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Abstract
Chronic pain syndrome continues to be a national health concern among all medical
specialties. It has an impact on the entire health care system and if current trends
continue, the economic impact alone will exceed 100 billion dollars. In 2014, 254
million prescription opioids were written in the United States. During this time, an
increase in prescription opioid related deaths was seen, with approximately 20,101 deaths
occurring in 2015. Properly trained clinicians across the health care system are needed to
achieve successful patient outcomes, while reducing cost, morbidity, and mortality. The
purpose of the scholarly project was to develop a comprehensive, opioid-specific, expert
reviewed and evidenced-based educational module for health care clinicians of all
specialties. Using the guidelines offered by the Center for Disease Control in 2016, the
content of the project was developed with a primary focus on the clinical processes,
pharmacological properties, and appropriateness of opioids in the treatment of chronic
pain. The educational module was disseminated to 10 experts in the field of pain
management and family practice. Each of them was asked to evaluate the educational
module and evaluate it from an expert standpoint via Likert-scale evaluation form. The
data revealed a median score of 4.5 out of 5 for most all categories, demonstrating the
project’s ease of use, evidenced-based content, and its ability to further expand the
knowledge of clinicians. The project will be presented to stakeholders and state
representatives for wide spread distribution. Educating health care professional over the
continuum will ensure effective social change and shift the current trends in prescription
opioid related mortality and morbidity.
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Section 1: Overview of the Evidenced-Based Project
Introduction
In the United States, chronic pain syndrome (CPS) is a common medical problem
and it is growing in prevalence (Chou, Ballantyne, Fanciullo, Fine, & Miaskowski, 2009).
Currently, there are 100 million sufferers and the cost to the health care systems has
reached over $100 billion (Chou et al., 2009). An estimated $5–10,000 is spent per
patient annually for medication management with opioid analgesics (Whitfill et al.,
2010). CPS is the leading cause of disability and loss of function in the United States
(Chou et al., 2009). Of the 100 million with CPS, about 7 million adults suffer moderate
to severe limitations in daily function, leading to a significant reduction in quality of life
(Chou et al, 2009). Disability compensation for CPS accounts for approximately $43
billion annually (Gatchel & Okifuji, 2009). According to Hart (2010), an estimated 149
million workdays are lost each year due to symptoms of chronic pain (Hart, 2010) and
accounts for an estimated $61.2 billion in lost productivity.
This reduction in quality of life and function, according to Neugebauer and
Heusser (2010), also leads to significant changes in the psychological status of this
population. It is common to see maladaptive psychological coping, often leading to fear,
avoidance, and anxiety toward treatment. These behaviors can produce ineffective
treatment and alter the patient’s perspective regarding care. The ability to provide
adequate pain relief has a direct impact on overall psychological health. The prevention
of psychological dysfunction can occur only when adequate treatment is implemented.
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Clinicians can often exacerbate this process by developing treatment plans with opioids
without proper training.
The treatment of CPS requires a comprehensive multimodality approach that
includes pharmacological, behavioral, interventional, and holistic management (Von
Korff, 2013). The use of the pharmacological approach has become more prevalent over
the last 20 years. It is estimated that 5.4–6.2 million chronic pain patients require daily
opioid treatments (Gudin, 2013). Clinicians along with federal and state regulators
recognize the need to balance adequate, legitimate medical treatment of chronic pain
against the misuse and diversion of opioids. The APS and the AAPM have developed a
multidisciplinary panel to provide evidenced-based guidelines for the use of
pharmacological approaches to chronic pain (Chou et al., 2009). These guidelines
recognize the use of two analgesic agents: short-acting and long-acting (Chou et al.,
2009). These guidelines support the use of the long-acting analgesics in the patient
population suffering from CPS (Compton & Volkow, 2006). This analgesic agent has
several clinical advantages over the shorter-acting version, including increased
therapeutic drug plasma levels, decreased peak–trough fluctuations, and prolonged
analgesic properties (Compton & Volkow, 2006). Additionally, most long-acting agents
allow for less frequent dosing and reduced end-of-dose failure (Compton & Volkow,
2006). Despite the recommendations by APS and AAPM, clinicians continue to prescribe
the alternative short-acting version of these medications (Rauck, 2009). The continued
use of this version often leads to a decreased therapeutic response, a higher addiction
probability, a higher tolerance rate, and a higher end-of-dose-failure (Compton &
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Volkow, 2006). The pharmacokinetic properties of these medications are important to
clinical outcomes in this patient population (Rauck, 2009). A primary reason for the lack
of compliance with the clinical guidelines has been identified as the education of the
health care provider (Von Korff, 2013). The goal of this project was to advance the
knowledge base of clinicians across the health care sector, which would allow them to
translate the guidelines into practice, with the intent of improving practice.
Problem Statement
Despite the advancements and practice guidelines that were established regarding
the use of long-acting pain medications, clinicians continue to treat chronic pain with
short-acting agents (Chou et al., 2009). According to Von Korff (2013), the use of shortacting medications in this patient population has proven to be ineffective and inconsistent
over the long term. Nurse practitioners are becoming more involved in the care of these
patients, and are often responsible for prescribing and maintaining pharmacological
treatments. Clinicians must be able to determine the most appropriate treatment in the
clinical setting, which often includes the use of one or more of these agents. Establishing
the most appropriate agent is paramount to producing effective, safe, and cost-effective
care. Until the knowledge of health care providers improves, short-acting agents will
continue to be used, leading to inconsistent and ineffective pain management (CDC,
2011).
Purpose
The purpose of the capstone project was to design and evaluate a clinicianfocused education module on the use of opioids to improve the knowledge base of health
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care providers in any setting, including medical doctors (MD), doctors of osteopathic
medicine (DO), nurse practitioners (NP) and physician assistants (PA). In this project, I
used the most up-to-date clinical guidelines developed by the Center for Disease Control
(CDC), APS, and the AAPM to support the project’s content. Clinical experts in the field
of chronic pain management and family practice were selected to review the educational
module and determine its appropriateness for clinician training. The end result of this
project was to create a continuing medical education (CME) module that would be used
by CME organizations to expand the knowledge of nurse practitioners and other
clinicians who are interested in the treatment of chronic pain. The anticipated result
would be improved patient safety, clinical outcomes, and overall management of patients
suffering from chronic pain. A complete measure of these variables will be conducted at
a later date following the academic setting.
Objectives
The main objective of this capstone project was to produce an expert-reviewed,
clinician-focused education module to help improve the way pain management is
provided to patients in the health-care settings when opioid analgesics are needed (Rauck,
2009). Experts in the field of chronic pain management and family practice were used to
provide an unbiased opinion on the usability, content, and expansion of knowledge of the
educational module by completing a post-educational survey, the expert-rating tool,
which was used to determine the module’s appropriateness for clinical use. This data
were collected and analyzed to determine if the module met the educational objectives
required of a CME. A standard five-rating Likert scale was used (see Appendix I).
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Practice Significance and Relevance
Regardless of a clinician’s specialty, the use of opioid analgesics in the practice
setting can create several practice concerns. (Gatchel & Okifuji, 2006). Clinicians who
use these treatment modalities inappropriately can suffer criminal and civil penalties
(Allen, Asbridge, MacDougall, Furlan & Tugalev, 2013). Clinicians need to be aware of
all regulatory guidelines and understand their responsibilities under these laws (Rauck,
2009). This is becoming extremely important to the practice of nursing, given the
expansion of scope of practice laws regarding nurse practitioners. Treatment decisions
need to be based on evidenced-based research; they need to be made with a thorough
knowledge of the standards of each of the federal and state regulatory agencies (Gatchel
& Okifuji, 2006). The failure to recognize and account for each of these practice concerns
can lead to significant licensure and criminal penalties in the practice setting (Gatchel &
Okifuji, 2006).
The development of an evidenced-based education module can provide clinicians
with the guidance to foster appropriate treatment modalities, while at the same time,
reducing the risk of inappropriate treatment for patients suffering chronic pain (Peiris et
al., 2014).
Tolerance and addiction needs to be addressed in the clinical practice setting
(Gudin, 2013). The use of long-acting opioids does not negate the risk of tolerance or
addiction; but they do provide the clinician with a means of reducing the oral intake of
these medications and peak-trough fluctuations that are commonly seen in the use of
short-acting opioids (Rauck, 2009). Reducing the number of orally consumed opioids can
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reduce a patient’s risk of developing tolerance over a short period of time (Gudin, 2013).
Opioid analgesics attach to the neurotransmitters and receptors in the brain and become
less responsive when multiple doses are taken over a short period (Gudin, 2013).
Receptor availability is directly related to the development of tolerance (Gudin, 2013).
The use of short-acting analgesics requires multiple doses throughout the day, which
inherently decreases the availability of these receptors and increases the risk of tolerance
(Rauck, 2009). The development of tolerance often leads to treatment failure in the
chronic pain population (Gudin, 2013). In contrast, the use of long-acting analgesics
decreases the development of tolerance by reducing the daily consumption of oral
analgesics (Gudin, 2013). The pharmacokinetic makeup of long-acting analgesics allow
for daily or twice a day dosing, while producing maximum therapeutic response (Gudin,
2013). This reduces the patient’s receptor utilization and reduces tolerance over the long
term (Gudin, 2013).
Addiction is seen in the chronic pain population and can produce practice and
patient safety issues (Compton & Volkow, 2006). Reducing a patient’s risk of addiction
is imperative when using narcotic analgesics in treatment (Compton & Volkow, 2006).
The use of short-acting analgesics produces several peaks and troughs during the course
of treatment (Rauck, 2009). These fluctuations can produce a physical need for this
medication in just a short period of time. In comparison, the use of long-acting agents
produces less of a peak and maintains stable plasma blood levels during the course of the
treatment (Rauck, 2009). These pharmacological properties can help reduce the
development of addiction over a short period, and can help produce a stable treatment
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environment (Compton & Volkow, 2006). The use of long-acting analgesics does not
negate the risk of addiction in this population, but they can slow the development of this
untoward effect (Rauck, 2009).
Finally, the risk of misuse and abuse of narcotic analgesics is a nationally
recognized concern in clinical practice (Compton & Volkow, 2006). The development of
long-acting analgesics has incorporated the use of abuse-deterrent formulations and
tamper-resistant tablets (Fine, Mahajan & McPherson, 2009). Extended release
formulations contain properties that inactivate the active ingredient when tampering
occurs (Fine et al., 2009). These formulations reduce abuse liability for the clinician and
protect the patient from toxicity that may occur from crushing, snorting, and injecting
long-acting opioid analgesic (Fine et al., 2009). This does not negate all the risk for the
clinician or patient. It is, though, a step toward reducing the misuse and diversion of
opioid analgesics.
Project Question
CMEs remain a primary tool, used by clinicians of all specialties to
increase their knowledge. Members of the pain management community and members of
the family practice setting often lack the training needed to implement evidenced-based
guidelines (Von Korff, 2013). The development of a comprehensive education module
that could be used by all specialties would likely further empower nursing professionals
and clinicians who are interested in the treatment of chronic pain. The following project
question applies to the current project: Does the evidenced-based education module meet
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the content requirements to further the knowledge of health care clinicians according to
the expert review?

Implications for Social Change in Practice
Clinicians across the country struggle to balance the need to manage the chronic
pain population against the numerous barriers in clinical practice (Compton & Volkow,
2006). These barriers are identified in the report issued by the Institute of Medicine, titled
“Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education,
and Research,” and include regulatory, legal, institutional, financial, and cultural barriers
(IOM, 2011). As nurse practitioners continue to gain autonomy in the prescribing of
opioid analgesics, they need further knowledge to develop appropriate treatment plans for
the treatment of their patient population. Clinicians, regardless of setting, must
understand the complex biological and psychological aspects of chronic pain, while
evaluating the available treatment options.
As with any chronic disease, management is an essential part of maintaining
function while reducing the risk of mortality and morbidity (Chou et al., 2009).
According to Institute of Medicine (2011) “Approximately 100 million U.S adults--more
than the number affected by heart disease, diabetes, and cancer combined--suffer from
common chronic pain” (p. 19). A substantial number of these patients classify their pain
treatment as inadequate. The IOM report also identifies inadequate treatment as the result
of barriers and providers’ misconceptions of patients suffering chronic pain. Providers
often presume that chronic pain patients misuse, abuse, and divert narcotic analgesics.
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These views present barriers that can lead to ineffective or inadequate treatment over the
over time. According to the IOM report (2011), “The majority of people with pain use
their prescription drugs properly, are not a source of misuse, and should not be
stigmatized or denied access because of the misdeeds or carelessness of others” (p. 145).
Significant attention needs to be directed toward the prescribing and management of
chronic narcotic analgesics in this population while removing the perceived judgment.
In addition to the clinician’s perception, another reason for the reluctance to
prescribe narcotic analgesics is the regulatory and legal implications (Compton &
Volkow, 2006). Federal and state drug prevention laws and enforcement practices
continue to make clinicians apprehensive to prescribe narcotic analgesics, even when it’s
clinically appropriate to do so (Compton & Volkow, 2006). This further complicates
access to care and contributes to the ineffective treatment of patients in this population.
The apprehension involved with the treatment of chronic pain often translates into an
attitude of denial and avoidance (IOM, 2011). The need to change the cultural and social
views on the treatment of chronic pain will be essential to providing effective treatments
in this unique population (IOM, 2011).
Nurse practitioners have an opportunity to improve the way chronic pain is treated
and viewed across the healthcare spectrum. Changing the social fabric will not be easy
and will require an expansion of knowledge over time. The development of an evidencedbased educational module will assist with the additional knowledge needed in the practice
setting (Peiris et al., 2014). While the development of such a module may not remove all
of the regulatory, legal, institutional, financial, and cultural barriers, it will certainly
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facilitate a greater level of confidence within the clinical practice. This capstone project is
expected to provide a useful educational tool for clinicians regardless of specialty (Peiris
et al., 2014).
Using opioid analgesics without proper knowledge can result in significant issues
for society as a whole (Compton & Volkow, 2006). In the United States, prescription
opioids are the fastest growing cause of drug misuse, which is leading to accidental
overdose and mortality, accounting for over 20,101 deaths in 2015. Studies tie this
directly to the increased rates of heroin use in the United States (IOM, 2011). Evaluating
the risk and benefits of long-acting analgesics is imperative when initiating a
management modality. The use of long-acting analgesics is often reserved for patient
populations that have explored and tried multiple other non-pharmacological treatment
modalities. This capstone will expand the knowledge of clinicians using these
medications; thus they will better understand how they should be used, and for whom.
Assumptions
1. It is assumed that the experts chosen for the purpose of this evaluation will be
unbiased.
2.

It is assumed that the information provided in the education will be accurate
and represent the most current and up-to-date evidence.

3. It is assumed that the experts will be similar in education and knowledge in
both clinical and academic settings.
4. It is assumed that the patients requiring opioid analgesics can gain access to
the medications that the continuing education module addresses. It is assumed

11
that the clinicians will be up-to-date on the resources needed to improve their
patient’s access to these medications.
Limitations
1.The number of experts reviewing the proposed educational module will be small
and only represent a portion of the experts available in the health care
community.
2. This education must be generalized, in order to be adequate for all specialties.
This may limit its usefulness for the pain expert.
Definition of Terms
The following definitions will help in understanding the nature of the project.
Chronic pain syndrome (CPS): Ongoing unpleasant sensations that last beyond
the standard healing period. Usually lasting greater than 3-6 months and affects quality of
life and function (IOM, 2011).
Opioid analgesics: Opioid (narcotic) analgesics are derived from the by-product
of Opium. They bind to opioid receptors in the brain, which are present in the brain and
nervous system. These receptors are responsible for the transduction of pain perception
(Gudin, 2013).
Long-acting opioid: Pharmacological compounds that attach to the opioid
receptors of the brain that have the ability to produce an extended period of pain relief,
typically greater than 8 hours (Gudin, 2013).
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Short-acting opioid: Pharmacological compounds that attach to the opioid
receptors of the brain that have the ability to produce duration of action typically shorter
than 4 hours (Gudin, 2013).
Pharmacokinetics: The process by which a formulation (drug) is processed
throughout the human body (Von Korff, 2013). It is a complete understanding of
absorption, distribution, metabolism and excretion of the selected drug. This process
occurs over a continuum and concurrently when a prescription drug is administered via
the oral, intravenous and intrathecal routes.
Pharmodynamics: The process or study of the chemical and physiological effects
of drugs on the human body (Von Korff, 2013). This includes the interaction between
opioid’s and mu-receptors in the body during administration.
Addiction: The presence of compulsive drug use and the continuous craving for
opioids for the use of the effects without concern for actual pain relief.
Tolerance: An uncontrollable neuroadaptation process that occurs overtime with
the use of analgesics agents that is characterized by a minimizing of effects of the drug
(Chou et al., 2009).
Neurotransmitters/Receptors: A chemical substance that releases when a nerve
impulse is stimulated. This transmitter causes a response within the nerve fiber and
distribution occurs throughout the selected fibers. The receptor is the location in which
the process occurs and the area where the transmitters attach themselves to produce the
desired effect.
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Therapeutic drug plasma levels: Therapeutic drug plasma levels refer to the
measurable amount of drug particulate in the blood that produces a therapeutic response.
This measure is performed often in toxicology testing or urine screenings. Threshold can
be over or under a predetermined value, representing toxicity or sub-therapeutic ranges.
End-of-dose failure: This process occurs when the selected opioid analgesic does
not produce the expected duration of relief, often leading to failure in treatment goals and
expectations (Compton & Volkow, 2006). This process can occur in both the short-acting
and long-acting versions of medications, however a higher prevalence is seen in the
short-acting version.
Clinicians: Health care providers involved in patient care including registered
nurses, advanced practice nurses, physician’s assistants, medical doctors and osteopathic
doctors of medicine. These professionals are responsible for direct patient contact and
care consistent with chronic pain management.
Evidenced-based guidelines: A set of recommendations that can be used by
clinicians that outline treatments and care for specific medical conditions (Sox & Stewart,
2015). These recommendations are based on the best research at the time the guidelines
are being developed. They should include an accurate representation of the literature (Sox
& Stewart, 2015).
Continuing medical education (CME): The process of providing clinicians with
resources, knowledge and educational experiences that improve or optimize professional
growth and performance. This project is tailored to Medical Doctors (MD), Doctors of
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Osteopathic Medicine (DO), Nurse Practitioners (NP) and Physician Assistants (PA). The
following describes the current requirements for each of these specialties:
● Physician/DO: (Category 1) Accreditation Council for Continuing Medical
Education. 2-year requirement: 100 credits with 20 credits designated to
category 1.
● Nurse Practitioner (10 contact hours in pharmacology) American Academy of
Nurse Practitioners. 5-year Recertification Requirements-100 contact hours of
continuing education (CE) required in the role of the nurse practitioners focus.
There is a 25-credit requirement designated for pharmacology only.
● Physician Assistants (Category 1) American Academy of Physician Assistants
(AAPA) Two, Four and Six Year Requirement- 50 Category 1 continuing
education credits for recertification.
Summary
CPS is a national health issue that requires the attention of all health care
providers, across all settings (Von Korff, 2013). Its negative impact on healthcare
expenditure and disability compensation is not sustainable over the continuum. Effective
and safe evidenced-based care is essential to reduce the overall mortality and morbidity
of this chronic disease. Nurse practitioners have a unique role in the successful treatment
of patients with CPS. However, evidence-based education needs to be implemented over
the continuum. The use of long-acting opioids provides a safe and cost-effective means of
managing patients with CPS. The pharmacological properties of these drugs decrease the
possibility of diversion and abuse and provide the clinician with reasonable safeguards. A
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change in the way clinicians prescribe these medications will only come with an increase
in knowledge that can be used in the clinical setting. This additional knowledge is
expected to help change the way clinicians think about and respond to patients with
complaints of chronic pain and thus increase the access this population has to effective
and efficient care. As is the case for all chronic illnesses, if health care providers turn
their backs on these patients and avoid treating them because of barriers, mortality and
morbidity will increase over the lifespan. Health care expenditures will continue to rise
and disability compensation will skyrocket. The expansion of practice allows the nurse
practitioner to be actively involved in the prescribing of opioid analgesics, while
participating in the development of evidenced-based and regulatory policies, ultimately
helping to change the social fabric.
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Section 2: Review of the Scholarly Evidence
A review of the literature was conducted using the following databases: CINAHL
Plus with Full Text, ProQuest Nursing & Allied Health Services, Medline with Full Text,
Health and Medical Complete, Ovid Nursing Journals Full Text and PubMed with Full
Text. The following search terms were used: nursing knowledge, chronic pain, narcotics,
and extended-release (long-acting), short-acting (instant release) and chronic pain
syndrome. These search terms revealed 1,552 articles using the databases listed above.
An additional exclusion criterion was implemented to prevent out of date articles and to
ensure each article was peer-reviewed. The two limiters set included: a 2008–2015 time
frame and only peer-reviewed articles. This limited search yielded 484 articles of which
30 met the literature specific criteria and were analyzed. It is important to note the CDC,
APS and the AAPM documents are primarily the sources being used to develop the
educational module.
General Literature
The treatment of chronic pain requires a comprehensive and multimodal approach
to be successful in achieving adequate pain control (Von Korff, 2013). The use of shortand long-acting opioid analgesics continue to be the predominant treatment method by
primary care health care providers and pain specialists. The AAPM and The APS view
the use of these medications as an essential element in the management of chronic pain
(Chou et al., 2009). A national review of these medications is occurring, specifically due
to the concerns related to education and training. The use of the short-term analgesics is
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becoming less attractive in the chronic pain community. Education about both agents is
lacking (Gudin, 2013).
Gudin assessed the value of long-acting agents in the chronic pain population.
Gudin (2013) demonstrated the effectiveness of these agents while demonstrating the
ineffectiveness of the shorter-acting version. The pharmacodynamic properties and
clinical advantages of long-acting analgesics are highlighted throughout the literature.
The delayed onset of these medications can produce a delayed systemic response,
therefore reducing the risk of addiction and tolerance. Additionally, the research outlined
the clinical advantages of these medications, including dosing, administration, decreasing
adverse events and minimizing of end-of-dose failure. The narrow fluctuations in overall
plasma concentrations compared to the short-acting version contribute to these clinical
advantages and improve the clinical effectiveness of the long-acting preparation.
Chou et al. (2009) published clinical guidelines that focused on the use of opioid
analgesics including the long-acting version. These guidelines and recommendations
were published after a panel concluded that long-acting agents are the best approach in
the management of chronic pain (Chou et al., 2009). The authors recognized standards set
by the AAPM and APS and each organization fostered the new recommendations
identified in the clinical guidelines presented. These guidelines were later updated and
research gaps were identified. Chou et al. (2009) revealed the need for adequate research
to clarify the importance of long-acting agents in the chronic pain population. The
uncertainty and confusion surrounding the use of long-acting agents continues to exist
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despite the available research. This continues to lead to clinician confusion and
inappropriate prescribing of short-acting agents.
The Institute of Medicine’s report, “Relieving Pain in America: A Blueprint for
Transforming Prevention, Care, Education and Research,” recognized the need for
improvement in all these areas and included a timeline that required recommendations for
these improvements (IOM, 2011). This report is considered a comprehensive roadmap in
the chronic pain community and exhibits commitment to addressing the shortfalls in pain
assessment and treatment. Additionally, this report focuses on the need to transform the
way our current health-care system deals with chronic pain patients and clinician
education (IOM, 2011). While the report is extensive and lengthy, it fosters the need for
additional education within the clinical setting. The report focuses attention on the use of
long and short-acting medications in the clinical practice (IOM, 2011). It establishes the
need for additional support for the use of both of these medications in all clinical setting.
The report did not directly support the use of a particular preparation, but it does support
a diagnosis-driven treatment plan. This includes the need for chronic medications for
chronic conditions (IOM, 2011). The authors recognize the limitations within this
recommendation and express the need to increase the literature base and clinician
knowledge before a full recommendation can be asserted (IOM, 2011).
In contrast, Fine, Mahajan & McPherson (2009) found that while the benefits of
long-acting analgesics revealed promise in the chronic pain population, short-acting
medications were still needed in some patients experiencing breakthrough pain (Fine et
al., 2009). This recommendation was revealed using the subjective behavior of the
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sample and the researches recognized this limitation within the study (Fine et al., 2009).
Research conducted by Rauck (2009) refuted this concept by demonstrating the
improvements in patient’s quality of life and improved treatment response with the use of
long-acting agents versus the short-acting preparation. In addition, this research found an
improvement in patient focus of daily activities and improved mental dexterity (Rauck,
2009). According to Rauck (2009), “ The body of data that supports the role of longacting opioids in chronic pain management and their beneficial effects on function, as
well as quality of life, and sleep, is more robust than that for short acting opioids”
(p.476). This research demonstrates the value within the medical community of the use of
long-acting opioid agent.
Specific Literature
The knowledge of health care professionals has a direct impact on how chronic
pain patients are treated in all settings (IOM, 2011). Although the literature is limited in
regards to what current knowledge exists among these professionals, there are concerns
that current knowledge in the outpatient and inpatient setting may be inadequate (IOM,
2011). A cross sectional study of over five hundred primary care physicians was
conducted at 12 academic medical centers throughout the United States (O’Rorke, Chen,
Genao, Panda, & Cykert, 2007). 572 primary care physicians responded to surveys that
were distributed in these each of these settings (O’Rorke et al., 2007). The sample
consisted of both female and male participants with a mean age of 35, while having a
mean of 7.6 years of practice (O’Rorke et al., 2007). A staggering 35% of the physicians
surveyed felt uncomfortable managing the chronic pain population (O’Rorke et al.,
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2007). Education was noted as the primary reason for the lack of comfort within the
sample (O’Rorke et al., 2007). The researchers concluded that additional education and
training increased the comfort of physicians and improved their willingness to provide
care to patients suffering from chronic pain symptoms (O’Rorke et al., 2007).
In contrast, the John Hopkins Pain Curriculum Development Team conducted
research in 2011 that examined current curriculum requirements of 117 U.S. and
Canadian medical schools regarding pain management education. Using the Association
of American Medical Colleges’ CurrMit database and 201 learning objectives developed
by pain experts, the researchers collected and analyzed data the findings using a
descriptive statistics approach (Mezei et al., 2011). Regression analysis was implemented
to compare and contrast the schools characteristics, while a standard T-test compared
CurrMit participants and non-participants (Mezei et al., 2011). Eighty-three (79.8%) of
U.S medical schools provided some education in pain management, however these
educational programs were general in nature and very limited in content and substance
(Mezei et al., 2011). In comparison, 92.3% of Canadian medical schools incorporated
pain management programs in their educational sessions (Mezei et al., 2011). The
researchers also found that each of these courses lacked substance and content that would
be reasonable to adequately prepare medical students for the treatment of chronic pain
(Mezei et al., 2011). The researchers concluded that significant gaps between pain
curricula and educational content existed (Mezei et al., 2011). Additionally, they found
that most of the courses reviewed in the research were short, limited and often
fragmented (Mezei et al., 2011). This resulted in a clear recommendation for a more
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organized and formal approach to education for pain management and care, including
lectures, workshops, learning labs, guest speakers and multidisciplinary panels (Mezei et
al., 2011).
Upshur, Luckmann and Savageau (2006) revealed a lack of knowledge and
training among health care professional in the community clinic population. The aim of
their research was to assess the provider satisfaction and knowledge for professionals
treating chronic pain. A total of 111 nurse practitioners, physician assistants, attending
physicians and residents were surveyed (Upshur et al., 2006). The survey questions used
were drawn from prior studies and validated by primary care providers, researchers and
board-certified pain specialists (Upshur et al., 2006). These questions varied in regards to
depth and included issues related to chronic pain management, opioid prescribing and
satisfaction with training and knowledge base for the delivery of care (Upshur et al.,
2006). The results of the research revealed a significantly low amount of health care
professional, 54.5%, who felt “prepared or knowledgeable” to prescribe opioids and treat
chronic pain appropriately (Upshur et al., 2006). This represents a large section of the
population and has significant implications in the treatment of chronic pain. Specifically,
the research indicated that education should be developed in a comprehensive setting
with a focus on patient-centered approaches, while aiming to improve providers’
concerns regarding substance abuse and addiction (Upshur et al., 2006).
Research conducted by Lewis, Corley, Lake, Brockopp and Moe (2015) used
professionally directed small group discussions to improve the knowledge of, and remove
barriers among, critical care nurses treating pain. The research used a quasi-experiment
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approach and was conducted in a 383-bed Magnet hospital in the southeastern United
States (Lewis et al., 2015). The sample size was relatively low at 34 participants, all of
whom were registered nurses that graduated from associate and baccalaureate degree
programs (Lewis et al., 2015). The experience among these nurses in managing pain
varied (0.25 to 23.0 years) with a mean of 7.92 years (Lewis et al., 2015). The Warden
Pain Knowledge Questionnaire (PKQ) was provided to participants and completed prior
to their designation to selected small groups (Lewis et al., 2015). This scale consisted of a
total of 24 true/false questions regarding the assessment and management of pain. A 5point Likert scale measured the time and energy nurses spent managing pain of patients
within the unit (Lewis et al., 2015). The intervention consisted of 10 small groups with
approximately 2 to 6 participants each, which met over a span of 2 weeks (Lewis et al.,
2015). Following the 2 weeks of small group discussions, the PKQ was administered
again to each participant (Lewis et al., 2015). Descriptive and inferential statistics were
used to calculate difference in knowledge within the groups pre-intervention and postintervention (Lewis et al., 2015). The researchers found a significant difference in
knowledge scores pre and post intervention (Lewis et al., 2015). The pre-intervention
mean was 18.28 (SD=2.33) while the post-intervention mean was 22.16 (SD=1.70)
(Lewis et al., 2015). This data revealed an increase in knowledge resulting from a basic
small group discussion educational technique, while reducing bias among the participants
(Lewis et al., 2015). The research had several implications for the hospital setting that
included the development of a pain steering committee and an increased awareness
among the nursing leadership regarding the lack of knowledge present in nursing units
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(Lewis et al., 2015). Lewis et al., (2015) recognized that clinical outcomes would only
improve once nurses increased their knowledge in a consistent and in-depth manner.
Finally, in one of the most comprehensive reports, The Institute of Medicine’s
report, titled “Relieving Pain in America: A Blueprint for Transforming Prevention, Care,
Education and Research”, identified three key recommendations regarding the education
and knowledge needed to transform the treatment of patients experiencing pain
symptoms (IOM, 2011). These recommendations include the need to redesign and
expand educational programs that focus on understanding pain, while improving
curriculums and continuing education programs for healthcare professionals (IOM,
2011). In conjunction with the American Society of Pain Management Nursing and The
Institute of Medicine, researchers recognized two key principles for the use of this
education to enhance the treatment of the chronic pain population (Lewis et al., 2015).
These two principles are to improve the clinician’s education and resources available to
support the clinicians practicing pain management and to offer ongoing education support
and research for widespread dissemination of evidenced-based analgesic practice (IOM,
2011). This comprehensive report illustrated the need for early education in pain
management as well as ongoing high-quality continuing education for physicians,
advanced practice nurses and ancillary staff that may be involved in the care of patients
suffering pain, especially those requiring opioid analgesics (IOM, 2011).
Conceptual Model
Malcolm Knowles introduced the theory of adult learning in the 1980’s and
outlined six principles that continue to be used today (Curran, 2014). Given the nature of
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the project, this theory is best suited to address the needs of the clinicians being targeted.
The six principles recognize that adults are internally motivated and self-directed; bring
life experiences and knowledge to learning experiences; are goal oriented, relevancy
oriented, and practical; and finally that adult learners like to be respected (Curran, 2014).
Malcolm Knowles’s Theory of Adult Learning
1. Autonomous & Self-Directed-The adult learner will be actively involved in
the learning process, and the facilitator will guide the process of learning with
a focus on the motivations and knowledge of the respective audience.
2. Life Experiences & Knowledge-The facilitator will provide the educational
modules in a manner that correlates with the learners’ current clinical or “life
experiences. Content will be driven toward real life situations.
3. Goal-Oriented-The facilitator understands the learners are enrolling to achieve
certain goals. The facilitator will ensure those goals are outlined and met.
4. Relevancy Oriented-Clinical situations and common clinical issues will
provide a focus that will make the educational module relevant to the learners
interest
5. Practical-Information that lack interest will be outlined in a manner that
demonstrates its importance in the clinical setting.
6. Respected-The prospective learner will be treated as equals and their
knowledge and experience will be respected in the development of the project
(p. 233)
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Additionally, these principles explore the adult learning process and the adult’s
ability to relate to the information provided (Curran, 2014). The course of education
relies on the clinicians’ (adults’) ability to learn, and if these principles are not observed
the project is likely to be unsuccessful in its attempts to expand the knowledge of the
targeted population (Curran, 2014).
Cox, Roche and Wynen (2011) used this theory to facilitate the examination of
retention of knowledge regarding pressure ulcers, using a lecture and computer-based
educational platform to present information to critical care and medical-surgical nurses.
A sample of 60 (N = 60) staff nurses from both units was obtained from a 500 bed
Magnet designated hospital in the northeastern of United States (Cox et al, 2011). The
theory’s principles were integrated into the lecture and computer based learning modules
(Cox et al, 2011). Each of these principles provided the researchers with structure to
optimize the learning in the critical care and medical-surgical units (Cox et al, 2011). The
use of this particular theory provided value to the nurses functioning within the units,
while allowing them the opportunity to apply the knowledge directly to clinical practice
(Cox et al, 2011).
In similar research, Schneiderman and Corbridge (2009) used the framework in
the evaluation of a computer-based learning module for arterial blood gas analysis. A
pretest and posttest design was implemented to assess the nurse’s abilities to interpret
arterial blood gas results before and after engaging in computer-based learning
(Schneiderman & Corbridge, 2009). A sample of 58 (N = 58) staff nurses from two
community hospitals in northern Illinois completed the educational modules and
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completed the appropriate pretest and posttest (Schneiderman & Corbridge, 2009). The
researchers followed the principles of the theory, and recognized that a better learning
experience would occur when the learner has a need to know and motivation for learning
(Schneiderman & Corbridge, 2009). According to Schneiderman and Corbridge, “Nurses
have a professional responsibility to maintain and update their knowledge, skills and
ability with regards to this activity to deliver safe, competent care and timely
intervention” (p.152). They also demonstrate that the use of continuing education allows
learners to build upon their previous clinical and educational experiences. The theory is
present throughout the literature and maintained in the computer-based educational
module (Schneiderman & Corbridge, 2009).
Finally, research conducted by Harne-Britner et al. (2009) applied this theory to
develop educational strategies to improve the medication calculation skills of nurses (N =
22) and senior nursing students (N = 31) at PinnacleHealth System and Messiah College.
The researchers reinforced the participants’ involvement by providing feedback
following their pretests, before implementing a 10-minute educational presentation
(Harne-Britner et al., 2009). The researchers furthered the use of the theory by providing
the participants the ability to choose the specific style of learning that most represented
their learning styles (Harne-Britner et al., 2009). The participants were also given
national benchmark data points regarding medication errors nationally and within the
organization itself (Harne-Britner et al., 2009). This provided the relevance needed to
enhance the learner’s education process (Harne-Britner et al., 2009). To further the
educational strategies following the research, self-study modules were provided to
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nursing educators and implemented within both organizations to enhance the learning
experiences and improve patient outcomes (Harne-Britner et al., 2009)
Summary
According to the literature, improvement in the education of all health care
providers is needed. Several gaps in the literature exist; these include the current
knowledge of physicians, nurse practitioners and physician assistants regarding the
current up-to-date treatments in pain management. There is a focus on curriculum
adjustments to ensure that new providers develop the necessary skills to treat the pain
population.
Malcolm Knowles’s Theory of Adult Learning is an appropriate theory for the
projects development. The principals of this theory focus on the adult learner and
integrate the life experiences of the learner. In addition to the focus on the adult learner’s
life experiences there is a level of respect that is maintained for the learner. The
educational module will be developed in a fashion that fosters the primary principals of
this theory and will be maintained throughout the dissemination process.
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Section 3: Methodology
Project Design/Methods
The educational module’s content drew on the clinical guidelines established by
the APS and the AAPM in 2009. This joint project brought together some of the leaders
in pain management, and consisted of 21 experts whose goal was to review evidence and
formulate recommendations for the use of opioids in chronic noncancer pain. The APS
and AAPM made several recommendations regarding patient selection, informed
consent, management plans, initiation and titration, short-acting medications use,
monitoring, and the treatment of high-risk patient populations (IOM, 2011). Additionally,
the panel offered strong recommendations on dosing, opioid rotation, and discontinuation
of therapy. These recommendations should be reflected in the practice of pain
management clinicians, but the pain management and primary care community recognize
the lack of knowledge of and adherence to these recommendations (IOM, 2011).
The continuing educational module was developed using a committee whose
members had extensive experience in the field of chronic pain management. Yeshvant
Navalgund, MD, Kimberly Jacob, NP-C, and myself were actively involved in the
planning, development, and implementation of the education module. Navalgund is a
national leader in the pain management community, with over 15 years of experience. He
is the chief executive officer of two separate chronic pain management centers, with over
17 offices under his direction. He holds board certifications from the American Academy
of Anesthesiologist and the American Academy of Pain Physicians. Dr. Navalgund is
actively involved in the pain community and spends several hours a week providing
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clinical and didactic education across multiple settings. Dr. Navalgund played an
important role in the development of content and guidance related to the pharmacological
aspects of the education. Additionally, Kimberly Jacob served in a role that supported the
development of the material that was presented to the experts. She was actively involved
in the development of topic selection and end product review. The development of the
content was under the direction of Dr. Navalgund and the committee chair.
As the principal educational project developer, I have the experience necessary to
ensure the validity of the project. I am a board-certified nurse practitioner in both family
practice and pain management, with over 15 years’ experience in the treatment of the
chronic pain population. As adjunct faculty at the University of Pittsburgh, I am actively
involved in the development and implementation of educational lectures for
undergraduate and graduate nursing students in anesthesia administration. My clinical
experience is significant. I continue to practice in the clinical setting, with an average of
20-30 patients under my care on a daily basis. My responsibilities include developing,
implementing, and monitoring plans for chronic pain patients who require narcotic
analgesics. Thus, I am well versed and up-to-date on the barriers and restrictions seen in
the treatment of this patient population.
As illustrated in the literature review, the need for education in the area of pain
management is well documented among all health care providers. This project is tailored
to medical doctors, doctors of osteopathic medicine, nurse practitioners and physician
assistants. The literature review demonstrated gaps in the knowledge of all these
professionals. One of the most successful approaches identified by experts in education is
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the use of continuing educational modules. This process allows educators the opportunity
to reach a vast array of medical providers in large numbers across multiple specialties.
There are several formats available for the development of continuing education. The
format chosen for this project was a standard written document. This format provides a
constructive, organized and easily referenced document that can be used by clinicians
throughout the health-care spectrum. However, if the content is not evidenced-based and
clinically relevant, the continuing educational module will not be approved for continuing
education credit. The content of the presentation focused on the treatment of chronic pain
with appropriate long-acting opioid analgesics. This included educational instructions
that align with the current standards of practice and clinical guidelines offered by the
APS and AAPM (see Appendix G and Appendix H).
Experts were chosen to review and evaluate the finished continuing educational
module and asked to provide feedback using the expert-rating tool. The committee
developed this expert tool since no current standardized tool exists in the educational or
clinical setting. Each expert was asked to complete a Likert scale (rating tool) to confirm
the appropriateness and validity of the project. The following criteria were needed to
deem the evaluator an expert:
1. Experts must be board-certified in a selected specialty (i.e. Pain Management,
Family Practice, Physical Medicine and Rehab)
2. Experts must be involved in the daily care of chronic pain syndromes (i.e.
Chronic Pain Syndrome, Complex Regional Pain Syndrome and Lumbar
Laminectomy Syndrome).
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3. Experts must have prescriptive authority and be actively involved in the
maintenance of short and long-acting opioid analgesics.
4. Experts must have experience in academia or be involved in continuing education
in some capacity.
Population and Sample
Given the nature of the project, the sample population were experts in the field of
various medical disciplines that are responsible for the daily care of patients suffering
CPSs. Ten experts in total participated. Seven of these experts were specific to pain
management as a specialty. The remaining experts were chosen from outside the
specialty to ensure other specialties are represented in the evaluation of the educational
module. The aim is to evaluate the content and presentation of the module and determine
its worthiness for submission for CME accreditation.
Data Collection
The experts were provided the educational module for review. A detailed
description of the intended focus of the project was provided to each expert before his or
her enrollment. The experts were asked to review the module and return the expert tool
once the review is completed. The tool consisted of questions that focused on the content
of the educational module to ensure its appropriateness and quality (See appendix B for
more information regarding expert tool). The experts were asked to return the responses
within 30 days of receiving the educational module and response form. They were
provided return pre-stamped envelopes for their convenience. Once a form was received,
it was labeled with the appropriate response number and locked in a secured location.
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The responses were not opened until all responses were returned. This observation was
reasonable for ensuring the correct data is extracted and recorded appropriately. This
ensured the answers are inputted as they appear on the response form. Each answer was
uploaded into an Excel file that was secured with password protection.
Protection of Human Subjects
Protection of human subjects was not an issue with this project given the
educational focus, however strict protocols were observed for the experts reviewing the
project. The expert review process occurred without the use of any personal information
and no information was retained following the return of the rating tool. No patients were
used, since the study is specific to improving the knowledge of health care providers. IRB
approval was still obtained according to the policy and a procedure of Walden University
The IRB approval number is 07-13-16-0495977.
Data Analysis
The data analysis was completed once all the experts completed their -rating of
the educational module. A standard descriptive analysis was used to summarize the data
obtained from the experts’ evaluations of the educational module.
Project Evaluation
The project was evaluated based on the responses of the chosen experts in the
selected specialties. The aim of this project was to design and develop a quality
educational module that is suitable for submission to a licensed organization that can
provide CME accreditation. The responses from the experts served as a foundation that
guided changes to the project. The expansion of knowledge for clinicians is an important
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goal of continuing education. This expansion of knowledge can only be obtained with
quality, evidenced-based education. The success of this project hinged on the approval
and acceptance of the content from the experts in the field. The evaluation occurred in
phases that include a formative evaluation, process evaluation, impact evaluation and
outcome evaluation (Friis & Sellers, 2009). The formative evaluation allowed for
modifications and improvement during the course of the development stages (Friis &
Sellers, 2009). This occurred over the course of the educational module. The process
evaluation allowed for reflection on the target population and the validity and consistency
of the information being provided (Friis & Sellers, 2009). This phase was emphasized by
the experts’ responses in the project. As for the impact evaluation, this measured the
impact on the clinicians that receive the educational module and the expansion of
knowledge that may occur (Friis & Sellers, 2009). Identification of this process occurred
once the content was established and the experts agreed that the module was worthy of
submission (Friis & Sellers, 2009). Finally, the outcomes evaluation focused heavily on
the experts’ feedback on the educational module (Friis & Sellers, 2009). This included
any recommendations that were made during the course of the evaluation. Collectively,
this information serves as an evaluation plan that works over the continuum and expands
beyond the academic setting.
Summary
The need for quality education on the use of opioids is needed in all healthcare
specialties. The use of evidence-based guidelines and treatment protocols should be used
to develop these educational modules. This project focused on the development and
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implementation of a high quality, evidenced-based educational module that can be used
in all specialties. A knowledge expansion is expected to occur with this module while
further expanding the nursing profession and help negate the risk involved with the use of
chronic opioid therapies in patients. The use of experts ensures the project meets the
goals of a high-quality, evidenced based module. The finished product is expected to
expand beyond the academic setting and be submitted to CME distribution companies.
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Section 4: Findings, Discussion and Implications
Summary of Findings
The goal of this project was to develop a comprehensive educational module on
opioid usage as a written document. This educational module was developed
collaboratively to expand the knowledge of clinicians who may encounter patients
suffering chronic pain and in need of opioid analgesics. This project is a peer-reviewed
educational module on the use of opioids in clinical practice. The need for quality
evidenced-based educational modules is highlighted in the literature, particularly in the
specialty of pain management (IOM, 2011). I ensured that the training being developed
would be clear and concise and that it represented up-to-date evidence. The educational
module was developed and provided to experts for assessment. A Likert scale was used
to assess the content and usability of the module (Appendix I). The Likert scaling system
for this project was as follows: 1 (complete disagreement), 2 (disagree), 3 (neutral), 4
(agree), 5 (strongly agree).
The 10-question evaluation form was designed to examine the project’s content
and instructional method (Appendix I). The data obtained from evaluation tool confirmed
the validity of the project while illustrating its importance in the education of health care
professionals.
Five physicians, four nurse practitioners and one physician assistant made up the
expert panel. All ten met the criteria listed in the previous section. All ten evaluations
were returned within 30 days. Table 1 lists the questions, the question type, median value,
and the experts’ rating for each question (as a percentage).
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Table 1
Expert Responses to Evaluation of Educational Module
Question

The content
is clear and
concise
The content
is capable of
expanding the
knowledge of
clinicians
The content
is appropriate
for clinicians
in general
and specialist
As an expert
in pain
management,
Would you
recommend
this education
to your
colleagues?
The content
demonstrates
the
importance of
using longacting
analgesics in
the CPS
The content
clearly
outlines the
medical and
legal
implications
to practice
and
community
when opioids
are used

Question
type

Median

1
(complete
disagreement) %

2
(disagree)
%

3
(neutral)
%

4
(agree)
%

5
(strongly
agree)
%

Content

4.5

0

0

0

50

50

Content

4.5

0

0

0

50

50

Content

4.0

0

0

20

50

30

Content

5.0

0

0

0

40

60

Content

4.0

0

0

10

50

40

Content

3.0

0

30

30

30

10

37
The
instructional
methods were
well
organized
The
instructional
methods
illustrate the
concepts well
The teaching
strategies
were
appropriate
for the
activity

Methods

5.0

0

0

0

20

80

Methods

5.0

0

0

0

20

80

Methods

5.0

0

0

0

10

90

Expert Evaluation Data
Content. The content questions one though seven measure the experts (N =10)
opinion on the educational modules effectiveness and appropriateness for clinical practice
and knowledge expansion. Five of the ten experts 50% (N =5) responded that they agreed
that the educational was clear and concise and capable of expanding the knowledge of
clinicians. The remaining five experts or 50% (N=5) responded with an opinion that they
strongly agreed with the modules ability to expand the knowledge and viewed it as clear
and concise. Question three demonstrated a different distribution in the answers and
included an opinion that were neutral in two 20% (N = 2) of the experts, while (N = 5)
50% of the experts agreed that the content was consistent with the current practice
standard and treatment guidelines. The remaining 30% (N = 3) experts strongly agreed in
their responses. Questions four and five demonstrated a correlation in the responses with
40% (N = 4) agreeing with the contents appropriateness for general and specialty practice
and their willingness to recommend the educational module to colleagues. The remaining
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60% (N = 6) experts strongly agreed with this assertion. Question six and seven of the
evaluation tool demonstrated a significant variation in the opinions provided by the
experts. Question six examined the expert’s opinion on the educational modules ability to
demonstrate importance of using long-acting analgesic in the chronic pain setting. One
expert 10% (N = 1) rendered the opinion as neutral; while 50% (N = 5) rendered the
opinion that they agreed that the education demonstrated the importance of the longacting agent. Four 40% (N = 4) opined that they strongly agreed with the educational
modules ability to demonstrate the importance of these medications. The seventh and
final question provided incite on the improvements that may be needed within the
educational project. The question addresses the medical and legal discussion within the
educational module and weather the implications are clearly outlined. The experts
provided opinions that demonstrated a need for additional improvements in this area of
the content. A total of 30% (N = 3) of the experts provided opinions in that fell below the
level of acceptance and disagreed with the modules ability to clearly state the medical
and legal implications. In contrast, only 10% (N = 1) of the experts strongly agreed with
the modules ability to state this content, while 30% (N = 3) agreed the module was
adequate in this content section. The remaining 30% (N = 3) experts opined that the
module was neutral in this regard.
Methods. A total of three questions were dedicated to the instructional methods
of the educational module. Questions one and two provided similar data from the experts
and 20% (N = 2) revealed agree with the organization and concepts of the module, while
the remaining 80% (N = 8) strongly agreed with the modules organization and concepts
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as it was presented. The final question addressed the overall teaching strategies used for
the education. A total of 90% (N = 9) strongly agreed that the strategies used were
appropriate for the module and content. Only 10% (N = 1) responded with an agreed
response in this section of the data.
In summary, the experts provided data that demonstrated the validity and
appropriateness of the pain management educational module. With the exception of
question seven, the experts overall agreed or strongly agreed with the content of the
educational module. The experts did not deem the medical and legal implication content
adequate and additional revisions will be needed prior to the implementation of the final
project planned after the academic setting. The data analyzed supports the content of the
module in all other aspects and support the education moving forward to the CME
process.
Implications
Policy impact. The DNP-prepared nurse practitioner is in a unique position to
guide and disseminate the need for improved health care policies in the chronic pain
arena (IOM, 2011). Their ability to critically evaluate the literature, health care policy
and clinical practice can be used to formulate the best practices and steer the health care
policies being developed. The ability to disseminate this information using the totality of
the evidence, while meshing daily clinical practice, provides a perceptive that has a direct
impact on how this policy should be developed. Several states across the country are
lacking the necessary health care policies that improve the pain management community
and the patient they serve (IOM, 2011). In the Institute of Medicine report titled
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“Relieving pain in America: a blueprint for transforming prevention, care, education, and
research” experts and policy makers recognize the need for quality evidenced-based
continuing education (IOM, 2011). This project is the first step in that process and
provide a foundation for lawmakers and state representatives as they consider health care
policy changes in pain management. Ensuring that clinicians are educated in the most upto-date approach and materials is imperative for the improvement of patient outcomes,
specifically in opioid prescribing (IOM, 2011). Given the current health concern and
mortality associated with opioid use, it is imperative that health care clinicians are
provided quality education and supported with appropriate health care policy (Friis &
Sellers, 2009).
In several states there are licensure requirements that require the clinician undergo
a required amount of hours of continuing education for selected topics including child
abuse, pain management and drug abuse before renewal of their license can occur,
however several states continue to lack the health policy needed to mandate this very
important process (Friis & Sellers, 2009). The national attention and the abundant
literature base surrounding education in pain management, specifically opioids, illustrate
the need for quality state mandated continuing educational modules (IOM, 2011). I will
disseminate the project to state and federal health care policy makers to demonstrate the
need for health care policies that support the mandate nationally. The educational module
will be used as a framework for the states that don’t currently have an opioid specific
educational mandate. This will shape the health care policy arena and shift the political
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awareness toward the education of the clinicians prescribing these medications on a daily
basis.
Clinical practice. The clinical practice of pain management continues to evolve
with the recent changes in the practice guidelines established by the CDC and AAPM
(Glowacki, 2015). The uses of continuing educational modules allow clinicians to
educate themselves on practice techniques that have proven to improve patient outcomes
(Glowacki, 2015). It is the clinician’s responsibility to translate the education into the
clinical practice (IOM, 2011). This project applies the most up-to-date evidenced based
guidelines and presents them in an expert-reviewed educational module that can be
applied directly to the clinical practice of pain management.
In a recent study conducted by The National Database of Nursing Quality
Indicator (NDNQI) titled “Coordinating Center for Dissemination and Implementation of
Evidenced-Based Methods to Measure and Improve Pain Outcomes” a total of 400
hospitals in the United States surveyed patients regarding their pain management while
being hospitalized (Glowacki, 2015). This research occurred in March of 2011 and
involved two phases that ended in December 2011 (Glowacki, 2015). Phase one resulted
in the development of interdisciplinary teams to manage the pain of patients while
hospitalized regardless of the pathology involved (Glowacki, 2015). One of the main
focuses of this interdisciplinary team was to provide evidenced-based staff education for
clinicians involved in the treatment of the pain population (Glowacki, 2015). The direct
result of this education, along with the implementation of pain management daily rounds,
improved patient outcomes and increased patients positive pain responses by 42.1 percent
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(41.2% to 83.3%) (Glowacki, 2015). The researchers recognized the significant benefit in
evidenced-based pain education and clinical practice changes occurred in 85% of the
hospitals involved in the two-phase research (Glowacki, 2015). These changes included
mandatory clinician and staff education for the treatment of pain in the inpatient
population (Glowacki, 2015). This research further illustrates the need for this education
in the pain community in order to implement quality practice changes
Research. Evidenced-based research in the pain management community started
to advance following the AAMP clinical guidelines offered in 2009, however prior to the
2009 report there was very limited effort placed on the proper prescribing of opioids
(Chou et al., 2009). In 2011, the Institute of Medicine's report determined that a lack of
education was one of the primary reasons for prescription medication abuse, diversion
and addiction (IOM, 2011). The IOM linked this to several factors in the research,
however one of the most significant findings was the limited education and knowledge
possessed by the prescribers, before and during, the administration of these medications
(IOM, 2011). This project provides a comprehensive educational module with a focus on
opioid prescribing and procedures that are necessary to provide safe, effective an efficient
care.
Research will need to continue once the project is completed and the academic
requirements are met. This includes the implementation and evaluation of the projects
content in a sample of clinicians. Research will examine if the module stimulates learning
and improves the knowledge of clinician (learner). Once this research is completed and
demonstrates an expansion in knowledge in the health care setting these findings will be
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disseminated to federal and state lawmakers. The intent and goal again will be to have
this educational module distributed as a mandatory continuing educational module for
clinicians with prescriptive authority, however without further research it is unlikely this
will be credible to persuade lawmakers. The additional research will also allow for the
perspective of the clinicians versus the current experts view. Additional adjustments may
be needed before wider distribution occurs.
Social change. The misuse, abuse and diversion of opioid analgesics are at an alltime high in the United States (Compton & Volkow, 2006). The social impact of opioid
misappropriation has created concern at both the state and federal levels (Compton &
Volkow, 2006). Mortality and morbidity continues to rise as a result of this
misappropriation (Compton & Volkow, 2006). Clinicians need to be prepared and
educated on the most up--to-date evidence to ensure these medications are not being
misappropriated by their patient (IOM, 2011). The assessment and identification of
potential problems prior to the initiation of opioids is essential and without proper
education this identification process can be complicated (IOM, 2011). If the clinician
does not recognize these potential problems it can place the clinician, patient and society
at further risk. The expansion of knowledge allows the clinicians the opportunity to make
decisions regarding the patient pain without the feeling of fear and apprehension (Lewis
et al., 2015). The education of our peers has proven over decades to improve patient
outcomes and create a shift in mortality and morbidity in other chronic illness including
heart disease, diabetes and cancer (IOM, 2011). This project, once fully implemented,
provides the foundation needed to achieve the expansion of knowledge to protect
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clinicians, patients and society as a whole.
Project Strengths and Limitations
Strengths. The evidenced-based educational module is easy to read and can
be accessed on any device that supports a Microsoft Word and PDF format. Experts in
the field of pain management have reviewed the module and the content was affirmed.
Therefore, the educational module demonstrates the content needed to improve the
knowledge of clinicians. The evaluation process allowed the experts to review the
module anonymously. This prevented any bias in the answers and allowed them to fill out
the evaluation tool without any preconception. This process allows the project to move
toward the next level and evaluate the impact in the clinical setting that will be
implemented post academic setting.
Limitations. The main limitation in the project’s development was
its inability to evaluate a sample of clinicians that are not considered experts. It does not
examine the actual knowledge expansion that is expected to occur in this population. This
project only demonstrates viewpoints of the expert and how they perceive the content of
the project. The measurement of knowledge expansion is going to be an important part of
the next phase of the projects success. The actual measurement of knowledge expansion
will further prove the validity of the project and reaffirm the projects benefit.
Recommendations for Remediation of Limitations in Future Work
The future work will need to include a separate measurement of the non-experts
opinion of the educational module and its content. Measurements will also need to
include pre and post testing of knowledge to accurately establishes the modules validity
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and worth in the from the non-experts standpoint. The data collected during this process
will further affirm the modules ability to improve the knowledge base of clinicians
prescribing opioid analgesics on a regular basis.
Analysis of Self
Practitioner. The conclusion of the DNP project offered areas of improvement
for me as a practitioner. The use of evidenced based practice is essential to ensure patient
outcomes are maximized (IOM, 2011). This project allowed me the opportunity to take
evidence-based guidelines and apply them to the educational process, which in turn,
resulted in a change in practice within the clinical setting. The translation of evidence
into practice is only achievable when the practitioner takes the necessary steps to review
the literature and recognize the changes that need to be made (Curran, 2014). This is
something that became very evident during this initial phase of the project development.
During the course of the project, I was able to translate the most up-to-date evidenced
based guidelines into my daily practice. The augmentations in my knowledge base
translated to the treatment of my patients and further research will be needed to determine
the direct impact.
Scholar. As a scholar, the DNP project presented me with an opportunity
to learn and grow during this 3-year process. The ability to evaluate the literature and
translate it into evidenced-based knowledge and education was an essential part of this
projects development. The scholarly inquiry necessary to produce a quality educational
module cannot be understated. This inquiry process led to an additional knowledge base
in my field and directly affects my patient’s outcomes and health.
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As project developer
As a scholar, the DNP project presented me with an opportunity to acquire
leadership skills during the development phase; implementation phase and evaluation of
the DNP project cannot be understated. The project development required vigorous
leadership and organizational skill. The leadership needed to manage and align all the
stakeholders, project members and content reviewers was one of the biggest
accomplishments of the entire project. This process defined me as a leader and without
proper leadership this process could not have been achieved. During the entire project
development, my hands on approach provided stakeholders, project members and content
reviewers with the support and leadership needed to ensure a successful project outcome.
Future Professional Development
The advancement of the DNP project has already had a significant impact on my
personal professional development. The growth of the proposal and educational module
provided a significant learning experience for me professionally. The enhancement in my
own education and understanding of pain management process was augmented by the
evidenced-based literature reviews. This process made me attentive to some of the most
up to date evidence that can now be applied directly to patients suffering CPS. In
addition, during the process of completing the DNP project there was an increased
awareness of the gaps and barriers present in the pain population. These gaps and barriers
are addressed in the educational module which will be disseminated to a larger audience
moving forward cannot be understated. This inquiry process led to an additional
knowledge base in my field and directly affects my patient’s outcomes and health.
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Section 5: Dissemination Plan
Introduction
The dissemination of the DNP project will be a process that occurs once the
project is implemented fully. One of the observed weaknesses of the project in its current
form is its inability to measure the actual knowledge expansion from the non-expert
clinician perspective. The larger portion of the project will occur following the academic
setting and will be implemented on a much larger scale, yielding a larger data set. This
data will be analyzed in similar fashion as the expert reviewed portion of the project.
Ultimately, The project will be dissemination using a written document format to state
and federal lawmakers in a face-to-face presentation. The intent and goal of this
presentation will be to make continuing education, regarding opioid management, a state
and federal requirement for any clinician with prescriptive authority that is wishing to
renew their license.
Furthermore, the project will be presented to multiple continuing educational
suppliers. This would include organizations such as Pri-Med Medical, American Nursing
Association, The American Academy of Nurse Practitioners and American Nurses
Credentialing Center. If accepted, this educational module will be disseminated to
multiple clinicians throughout the health care setting. This will provide the education
needed to enhance the pain management community.
Summary and Conclusions
The DNP project presents an evidenced-based educational module that focuses on
the use of opioid analgesics in the clinical setting. The experts in pain management
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reviewed this project and the content was affirmed by their responses on the evaluation
tool provided. The median score for questions 1 and 2 was 4.5, while questions 4, 5, 8, 9
and 10 scored a median score of 5.0. The lower of the two median scores (4.5 and 3.0)
occurred on questions 3, 6, and 7, which will be addressed in the next phase of the
project. The median and raw scores demonstrate a clear understanding of the content
while enhancing the validity of the projects purpose.
In summary, the DNP project will provide value to the health care community and
the clinicians treating patients that suffer chronic pain. This patient population is often
complex and may require the use of opioids analgesics throughout their care. Without a
proper knowledge base, patient outcomes can suffer, leading to a further burden on
society (IOM, 2011). Continuing education and the expansion of knowledge have proven
to improve patient outcomes in other chronic conditions including heart disease, diabetes
and several forms of cancer (IOM, 2011). Significant emphasis is being placed on
clinicians treating chronic pain and the need to practice with the most up-to-date evidence
has never been more imperative. The use of a quality evidenced-based educational
module will assist the clinicians in their clinical practice and allow them to practice
within the current guidelines while maintaining a standard of care (IOM, 2011). Thus,
producing a more informed clinicians base while improving patient outcomes though the
duration of their treatment.
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Appendix A: An Evidenced-Based Pain Management Module to Improve the Knowledge
of Clinicians
Patient Selection and Diagnosis:
Physical Examination and History
A. Complete assessment of physical health
1. Complete medical history-pain specific.
2. Identification of co-morbidities
3. Appropriate Diagnostic Testing (Ordering/Obtaining)
4. Complete physical examination, including
documentation of painful elements and findings
5. Clarifying and establishing opioid appropriate diagnosis
Physiological Assessment and History
A. Complete assessment of psychological health
1. Identification of pre-existing psychological disorders
a. Personal history of abuse/addiction
b. Family History of abuse/addiction
c. Psychosomatic Underpinning
2. Risk Assessment Tools
a. Screener and Opioid Assessment for Patient
with Pain (SOAPP)
b. Opioid Risk Tool
c. Diagnosis, Intractability, Risk, Efficacy (DIRE)
Tool
d. CAGE
II. Informed Analgesic Consent/Management Plans:
1. Risk/Benefit Analysis:
a. Documentation
b. Patient Awareness.
c. “RED FLAGS”
2. Goal Setting/Planning
a. Functional Improvements
b. Physiological Improvements
c. Social Indications
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3. Monitoring
a. Urine Drug Screening
b. Random Pill Counts
c. Genetic Testing-New Technology
d. High-Risk Populations

4. Opioid Treatment Agreement
a. Documentation Standards
b. Patient Requirements
c. Frequency of renewal
III. Drug Selection and Appropriate Use for Chronic Non-Malignant Pain
1. Short-Acting Analgesics
a. Literature Review/Diagnosis Appropriate Care
b. Efficacy
c. Pharmacokinetics/Pharmodynamics
d. Side Effects/Adverse Reactions
e. Initiating Therapy
d. Outcome Measures
2. Long-Acting Analgesics
a. Literature Review/Diagnosis Appropriate Care
b. Efficacy
c. Pharmacokinetics
d. Side Effects/Adverse Reactions
e. Initiating Therapy
d. Outcome Measures
3. Maintenance
a. Follow up Consultations/Documentation
b. DEA Reporting
c. Pharmacy Reporting
d. State Databases
IV. Legal Implications for Advanced Practice
a. Current Federal Law
b. Current State Law
c. Prescribing Implications
d. Case Studies/Legal Examples
V. Current Clinical Guideline Review
a. American Pain Society

57
1. Opioid Treatment Guidelines
b. American Academy of Pain Medicine
1. Opioid Treatment Guidelines
c. Centers for Disease Control and Prevention
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Appendix B. Opioid Analgesic Educational Module
Introduction:
The use of opioid analgesics for the treatment of CPSs continues to be
controversial in the absence of cancer related pathology (Compton & Volkow, 2006). It is
imperative that direct and indirect health care providers treating chronic pain utilize the
most up-to-date literature and guidelines available to develop and manage the treatment
plans in this patient population (Chou et al., 2009). In 2015, it is estimated that 20% of
patients presenting to health care providers reporting pain received opioid analgesics
prescriptions (Dowell, Haegerich & Chou, 2016). In the United States, opioid
prescriptions have escalated significantly over the last several years. In 1991 it is
estimated that roughly 40 million prescriptions were written compared to 259 million in
2012 (Dowell et al., 2016). This is enough for every man, women and child in the United
States to have their own prescription bottle (Dowell et al., 2016). The escalation in opioid
prescribing undoubtedly had an impact on the increase of addiction and non-medical uses
of these prescriptions (Dowell et al., 2016). While there is limited literature to directly
relate the two, several statistical trends appear problematic. In the time period between
2004-2008 emergency room visits increased by 111% for non-prescription opioid related
uses, overdose deaths became the second leading cause of death in America and an
estimated 7 million Americans were abusing some form of prescription opioids (Dowell
et al., 2016).
These problematic statistics reinforced the need for clinical guidelines, stricter
regulations and formative treatment protocols for clinicians treating patients with chronic
pain. In 2009, The APS and The AAPM published guidelines titled “Clinical Guidelines
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for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain”. This joint document
serves as a nationally recognized set of guidelines for clinicians that treat chronic pain
(Chu et al., 2009) In 2011, The White House Office of National Drug Control Policy
echoed the recent guidelines and emphasized the need to maintain legitimate medical
treatment of pain while reducing the risk of opioid abuse and death (Dowell et al., 2016).
Shortly after the White House published their initiative, The U.S Food and Drug
Administration released the Risk Evaluation and Mitigation Strategies in 2012,
commonly referred to a REMS, which focused on the education of clinicians as it relates
to the use of extended-release (ER) and long- acting (LA) opioid analgesics (Dowell et
al., 2016). Most recently, The Center for Disease Control (CDC) released a new set of
guidelines titled “CDC Guideline for Prescribing Opioids for Chronic Pain, United
States, 2016. These guidelines are the most comprehensive to date and included input
from stakeholders, experts, public representatives, peer reviewers and federal advisory
committees (Dowell et al., 2016). The CDC intended to bridge the communication gap
between clinicians and patient regarding the risk and benefits of long term opioid therapy,
while improving the safety and effectiveness of pain treatments (Dowell et al., 2016). The
value of these guidelines remains to be seen but are being reared as some of the most
comprehensive and in-depth published opioid guidelines (Dowell et al., 2016).
Local, state and federal officials identified education and training as being one of the
most effective avenues to facilitate and combat the current opioid crisis (Institute of
Medicine, 2011). This CME exposition will provide clinicians with a structured
foundation to practice with vigilance when opioid prescriptions are needed to control pain
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chronically. It will serve as the first step in defining and furthering the education of
clinicians interested in the safe, effective and efficient treatment of the chronic pain
population.
Patient Assessment, History and Physical Examination
Assessing patients for the use of chronic opioid therapy in noncancerous chronic
pain is a process that all clinicians should be well versed and fluent in preforming
(Jamison, Serraillier & Michna, 2011). This process is multifactorial and requires a
significant documentation process in order to comply with state and federal regulation.
The inherent risk of prescribing opioid medications can only be reduced when clinicians
are provided education that represents the most current clinical guidelines available
(Jamison et al., 2011). The current published clinical guidelines demonstrate a need for
particular elements that include a complete documented assessment and medical history,
verification of all current medications, detailed physical examination, current
psychological status and substance abuse history (Dowell et al., 2016). Each of these will
be addressed in detail, ensuring a complete understanding of the elements needed to be in
compliance.
Patient Assessment
A comprehensive approach needs to be taken when addressing the assessment and
medical history of a patient suffering from noncancerous related pain, especially when
opioid analgesic is being considered in the treatment plans (Jamison et al., 2011).
Ancillary staff and clinicians practicing pain management should be aware of the
necessary elements needed to meet the minimal standards set forth in the clinical
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guidelines offered by The American Academy of Pain Medicine and The Center for
Disease Control (Jamison et al., 2011;Dowell et al., 2016). These minimal standards
include a detailed description of the following (Jamison et al., 2011;Dowell et al., 2016):
A. Locality of pain symptoms
1. Current location of the pain including any areas that the pain may radiate
to.
2. Multiple pain complaints to be address individually.
B. Onset of pain
1. When the pain started (post-surgical, motor vehicle accident ect)
2. Duration of symptoms (short term intermittent, long term continuous)
3. Timing (When it is better or worse)
C. Characteristics of pain (detailed description, i, e., aching, throbbing, sharp or
shooting)
1. Throbbing
2. Aching
3. Sharp
4. Shooting
5. Burning
D. Pain scoring/Intensity (current pain, best pain, worst pain)
1. Numeric Pain Scale (0 to 10 scaling system)
2. Verbal Descriptor Scale (utilizes six phrases starting with no pain to worst
pain)
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3. Visual Analogue Scale (VAS) (Rating system using patients marking on a
line)
4. Oucher Scale (culturally sensitive pediatric scaling system)
5. Comprehensive McGill Pain Questionnaire (sensory component)
Several scoring systems currently exist and consideration must be given for
cultural, development stage, cognitive function and language barriers of the patient.
E. Exacerbating/Alleviating factors
1. What activities make the pain worse?
2. What activities make the pain better?
3. What medications reduce the pain?
4. What interventional treatments improve the pain?
5. What holistic treatments improve the pain?
F. Associated Symptoms
1. Sleep Disruptions
2. Mood alterations
3. Appetite
4. Socialization and family relationships
5. Sexual activity
6. Activities of daily living
G. Current and Past Treatment
1. Interventional treatments (injection therapy, surgeries, holistic care)
2. Physical therapy/chiropractic care (document number of sessions)
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3. Past medication usage (NSAID’s, opioid’s, muscle relaxants)
Aside from compliance, these assessment elements will assist the clinician in
defining the etiology of the patient’s painful symptoms (Kulich &Stone, 2012).
Clinicians must be cautious when treating painful symptoms with opioid analgesics and
ensure that the diagnosis they are treating is appropriate (Kulich &Stone, 2012). There
are two main pain categories that are clearly defined in the literature. These two
categories include nociceptive and neuropathic pain processes (Allen et al., 2013)
Nociceptive pain is best described as pain that results from damage to an area or
areas of body tissue (Atluri, Akbik & Sudarshan, 2012). It is due to the activation of
specific neural pathways that sense damage to the tissue or the possibility of potentially
damaging stimuli (Atluri et al., 2012). The activation of C fibers, A-delta and A-beta
neurons transmit the painful signals to the brain (Atluri et al., 2012). It is typically a
benign process, however can be related to cancerous involvement. In most cases the pain
can be directly related to bony structure, muscle and joint pathology (Martel et al., 2014).
Nociceptive pain is usually described as sharp, aching and throbbing, that is persistent
and can vary in intensity (Atluri et al., 2012; Martel et al., 2014). This particular pain
processes is very responsive to opioid analgesics and is supported in the literature (Atluri
et al., 2012; Martel et al., 2014). Given the response to opioids, patients that suffer from
nociceptive pain are considered ideal candidates for opioid therapy (Atluri et al., 2012;
Martel et al., 2014).
In contrast, neuropathic pain can be directly related to damage to a specific nerve
or a group of nerves (Atluri et al., 2012). This damage occurs at the level of the neurons
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in the human body that has become injured or damaged (Atluri et al., 2012). This
insult/damage results in abnormal messages of pain being sent to the central nervous
system and brain (Atluri et al., 2012). These abnormal signals travel in the nerve pathway
that result in sensations of pain that are consider dysfunctional. The pain is typically
described as shooting, burning, tingling and numbness (Atluri et al., 2012; Martel et al.,
2014). In chronic noncancerous pain, this process can be related to co-morbidities and
diagnoses including diabetes, previous surgery, infection and trauma (Atluri et al., 2012;
Martel et al., 2014). It is noted in the literature that the use of opioids in this patient
population should be avoided and they are minimally responsive when neuropathic pain
is present (Atluri et al., 2012; Martel et al., 2014).
Appropriate management techniques can only be developed when the
differentiating factors are properly assessed. There is a clear distinction between
nociceptive and neuropathic pain symptomology and the clinician should be clear when
documenting these differences (Von Korff, 2013). It is well established in the current
guidelines that pain evolving from the neuropathic pain processes is minimally
responsive to opioid analgesics (Chou et al., 2009; Dowell et al., 2016). There are several
theories as to why the responsiveness of opioid analgesics is reduced in the neuropathic
process, but one continues to be most predominant in the literature. The functional
change that occurs at the level of the dorsal horn of the spinal cord during neuropathic
pain processes causes a noted downregulation or desensitization of the μ-opioid receptors
(Chou et al., 2009). This ultimately leads to a reduced in the overall responsiveness of the
opioids and reduces ability of the μ-opioid receptors to be affected by the opioid
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medication (Chou et al., 2009). This is not to say that they should not be used, however it
should be considered second or third line treatment option.
Physical Examination:
The physical examination that focuses on the pathology of noncancerous pain
must comprehensive and systematic (Sox & Stewart, 2015). The standard physical
examination should apply and the clinician should exam the basic systems involved in a
complete examination. This includes documentation of the cardiovascular, respiratory,
abdominal, musculoskeletal and neurological systems (IOM, 2011). A focused evaluation
should include an in depth assessment of the motor and sensory function of the patient to
include documentation of any painful or decreased sensory response to testing (Sox &
Stewart, 2015). The documentation should reflect correlation with pain patterns and the
suspected or known pathological processes (Sox & Stewart, 2015). The patient
complaints should direct the clinician to perform a focused examination while narrowing
the differential pain diagnosis. Careful observation of verbal and non-verbal pain
behaviors should be examined and documented (Sox & Stewart, 2015). These include the
patient’s ability to sit in a chair, gait, position changes and use of assistive devices (Sox
& Stewart, 2015). Each clinician should utilize their own structured examination;
however the documentation should reflect the appropriate examination of the painful
areas. There are no clinical guidelines for the specific physical examination requirements
nevertheless a detail examination should occur (Chou et al., 2009).
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Co-morbidity/Medical History Assessment:
The assessment of a patient’s medical history and comorbidities is particularly
important when deciding on the integration of opioids analgesics into the treatment plans
(IOM, 2011). Aside from the assessment of these conditions, it is imperative that
documentation reflects all of these conditions and the clinician must address how they
will be managed. Assessment of prior medical history can occur via patient report or
previous medical record reviews (IOM, 2011). The importance of obtaining and
reviewing a patient’s prior medical history with primary care, specialist and
hospitalizations cannot be understated (IOM, 2011). These records will often reveal a
patient’s previous history that may be a contributing factor in the decision making
process (IOM, 2011).
The clinician should use extreme caution when prescribing in patients that suffer
from any sleep-disordered breathing (IOM, 2011). This would include patients with heart
failure, sleep apnea and obesity (IOM, 2011; Sox & Stewart, 2015). It is essential that
clinicians monitor the titration of opioids in patents that suffer altered respiratory
function. Opioid analgesics should be avoided in all cases that are classified as moderate
to severe in nature. This includes uncontrolled congestive heart failure and sleep apnea
requiring continuous positive airway pressure (CPAP, IOM, 2011; Sox & Stewart, 2015).
In milder cases, opioids can be used, however very careful titration should occur and
continuous monitoring is crucial in order to minimize the potential for overdose and
death (Sox & Stewart, 2015).
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Obesity is a major health risk and concern when treating chronic noncancerous
pain with opioid analgesics (Lewis et al., 2015). The respiratory insufficiency and
respiratory depression that occurs in patients presenting with a body mass index (BMI) of
30 or greater pose the greatest risk (Lewis et al., 2015). It is estimated that patients that
fall into this classification have a 45% greater chance of developing a significant
respiratory insufficiency in comparison to patient that present with a BMI of 25-29
(Lewis et al., 2015). The risk is negated further when patient present with a BMI of less
than 25 (Lewis et al., 2015). Caution and careful attention should be taken when starting
and titrating opioid analgesic of any kind in this population. Consideration for weight loss
evaluation or pulmonary testing may be needed prior to the initiation of these
medications (Lewis et al., 2015).
Patients with renal and hepatic function insufficiency also pose a risk when
opioids are being prescribed or considered (IOM, 2011). Clinicians need to use extreme
caution when prescribing opioids in this population given the inability of the body to
excrete the drug efficiently (IOM, 2011). If renal or hepatic excretion is not optimized
accumulation of opioids may occur, reducing therapeutic windows and causing
respiratory depression and overdose situations (IOM, 2011). Routine lab values should be
obtained in any patient that has a history or concern for renal or hepatic insufficiently
(Lewis et al., 2015). Hepatic and renal function panels should be ordered prior to the
initiation of the selected opioid and routine follow up testing should be performed every 3
months (Lewis et al., 2015). Documentation should present a complete review of these
laboratory values with notation of any abnormal values prior to and throughout treatment
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(Lewis et al., 2015). This is especially the case in combination medications including
Hydrocodone/Acetaminophen (Vicodin) and Oxycodone/Acetaminophen
(Percocet)(Lewis et al., 2015). These two opioids analgesic have been linked in the
literature to significant damage to the hepatic system is patients requiring regular
frequencies and dosing (IOM, 2011).
Advanced age is a significant factor when deciding if opioid analgesics are
appropriate and safe for a patient suffering pain symptoms (IOM,2011). Clinical
guidelines recommend that any patient over the age of 65 years be closely monitored and
all alternatives be considered prior to implementing the use of opioids (IOM, 2011).
There is an inherent risk given the reduced renal function and medication clearance that
occurs in advanced age (IOM, 2011). This is true even in the absence of underlining renal
disease. There is a very thin line when renal function declines in advanced age, making
the therapeutic window small making normally safe doses unsafe in this population
(IOM, 2011).
Additionally, cognitive function needs to be assessed prior to considering opioid
therapy in the older adult. Education and counseling should be provided to negate the risk
associated with declining cognitive function (IOM, 2011). Clinicians should be
concerned with cross interaction with multiple medication use, constipation and incorrect
dosing schedules (IOM, 2011). Interventions should be implemented to avoid and combat
these issues prior to starting opioids in a patient of advanced age. Fall risk assessments
should be conducted to ensure the use of the opioid wouldn’t further exacerbate an
already unsafe situation (IOM, 2011).

69
Finally, the female adult population needs to be evaluated for the possibility of
pregnancy prior to and during treatment with opioid analgesics (Chou et al., 2009;
Dowell et al., 2016). Mother and fetus are at increased risk should opioids be continued
during the development stages of pregnancy (Chou et al., 2009; Dowell et al., 2016). The
literature demonstrates a clear correlation of stillbirth, poor fetal development, pre-term
delivery and early child defects when opioid analgesics are used during pregnancy (Chou
et al., 2009; Dowell et al., 2016). Current guidelines from the AAMP and CDC suggest
the use of opioids in pregnancy should be avoided unless the benefits outweigh the risk
(Chou et al., 2009; Dowell et al., 2016). It is estimated that 50% of opioid dependent
mothers will have a child with opioid-induced withdraw (Dowell et al., 2016). Should
opioids be absolutely required, a specialist with experience in neonatal withdrawn should
be present for delivery (Dowell et al., 2016). It is imperative that clinicians provide and
document that a discussion occurred regarding these inherent risk and potential
complications (Chou et al., 2009; Dowell et al., 2016). Birth control techniques should be
addressed with each adult female of childbearing age during initial assessment (Chou et
al., 2009; Dowell et al., 2016).
Physiological Assessment:
It is imperative that a thorough evaluation and documentation of the
psychological impact of pain on the patient be conducted (Bussing, Ostermann,
Neugebauer, & Heusser, 2010). Clinical depression, anxiety and stress are associated
with chronic pain in the literature (IOM, 2011; Bussing et al., 2010; Arteta et al., 2016).
If left unaddressed it can undermine the treatment of the patient and exacerbate the
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current symptomology (Arteta et al., 2016; Bussing et al., 2010). Several evaluation tools
that address and identify these potential psychological conditions exist in the literature
and practice. Clinicians should avoid using a single tool or method when conducting a
psychological evaluation of a patient to avoid biases and manipulation of the testing
(Arteta et al., 2016; Bussing et al., 2010). The inclusion of spouses/partners, family
member and close friends is critical and valuable to the assessment of the psychological
health state of the patient suffering chronic pain and should be implemented whenever
possible (Arteta et al., 2016; Bussing et al., 2010).
The most common and tested tools include Personal Interviews, Psychosocial
Pain Inventory, Pain Assessment Report, The Minnesota Multiphasic Personality
Inventory (MMPI) and The Patient Health Questionnaire (PHQ-4)(Arteta et al., 2016;
Bussing et al., 2010). The personal interview process is one of the most commonly used
approaches to identifying and obtaining psychological information (Bussing et al., 2010).
This process includes very directed question with the patient and family that focus on the
identification of potential problems areas that may require further evaluation. The
clinician should pay particular attention to the input from other sources during the
personal interview (Bussing et al., 2010). The relationships and interactions with others
can provide valuable information into the psychological state of the patient during
everyday interactions and periods of stress and pain (Bussing et al., 2010). Theoretical
perspective of the clinician plays a role in this process and the variables need to be
considered during the patient-clinician interaction (Bussing et al., 2010).
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The Psychosocial Pain Inventory is a 25-question interview process that allows
the participant and interviewer the opportunity to expand of topics that may affect
treatment (Arteta et al., 2016; Bussing et al., 2010). The primary psychosocial factors
evaluated in this instrument include pain behavior, social reinforcement, lifestyle
changes, secondary gain (litigation), economic status, alcohol/drug use, prescription
medication use, coping strategies, social environment and interaction, current stressors
(Arteta et al., 2016; Bussing et al., 2010). The assessment also addresses the patient’s
personal, family and medical histories over the course of the lifespan. Additionally, it
evaluates the reactions and coping with current pain related treatments and outcomes
(Arteta et al., 2016; Bussing et al., 2010).
The Pain Assessment Report is another valuable interview process that is semistructured and quantifiable (Arteta et al., 2016; Bussing et al., 2010). The information is
obtained in a specific format and the questions are coded in measureable terms. Each of
these questions focus on a specific domain that includes history, presumed diagnosis of
pain, patient factors influencing the pain experience, illicit substance/alcohol use and
cognitive, behavioral and physical means of coping strategies (Arteta et al., 2016;
Bussing et al., 2010). Additional information is obtained regarding pain related changes
in relationships with family, friends and significant others (Arteta et al., 2016; Bussing et
al., 2010). A larger emphasis is placed on social and psychological functioning including
mood, sleeping patterns and previous psychological treatments (Arteta et al., 2016;
Bussing et al., 2010).
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The Minnesota Multiphasic Personality Inventory (MMPI) is another commonly
used assessment tool that aims to parallel pain and personality (Arteta et al., 2016;
Bussing et al., 2010). The MMPI is currently being administered is two separate formats.
This includes the MMPI-2 that contains 567 questions that are answered in true or false
format and address 10 clinical scales, 10 subscales that measure abnormal psychological
behavior (Arteta et al., 2016; Bussing et al., 2010). Built in validity testing is present
within the assessment and allows the clinician the opportunity to measure general test
taking attitudes (Arteta et al., 2016; Bussing et al., 2010). In 2008, the MMPI-2-RF was
published and is considerably shorter and only consists of 338 true/false questions (Arteta
et al., 2016). The subsections are limited in the newer version and the typical time of
testing is roughly 30-40 minutes (Arteta et al., 2016). The MMPI-2 is well established in
the literature and is the used frequently considering the familiarity in the medical and
psychological community despite its length of time it requires to administer (Arteta et al.,
2016).
Finally, The Patient Health Questionnaire (PHQ-9) is one of the widely
recognized depression assessment tools for the use in the clinical setting (Arteta et al.,
2016). It provides clinicians with a multipurpose tool that can be used for screening,
diagnosing, monitoring, and measuring the severity of depression symptoms (Arteta et
al., 2016). This tool is scored with ease and can be administered several times throughout
treatment to establish improvements and setbacks (Arteta et al., 2016). The questions
focus on the patient symptoms, within the prior 2 weeks to testing, and include suicide
related questions (Arteta et al., 2016). In recent months, the first two question of the
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assessment have been incorporated into several quality improvement measures including
the Physician Quality Reporting System (PQRS)(Arteta et al., 2016). This national
program recognizes the importance of early identification of depression in the pain
population and all health care population seeking treatment (Arteta et al., 2016).
The above psychological assessments are just a guide and each individual
clinician should decide on the best tool for their patient population and medical practice
(Arteta et al., 2016). Whenever possible, it is recommended that the clinician treating
non-cancer chronic pain align themselves with mental health professionals that have
experience in the treatment of pain related psychological disorders (Arteta et al., 2016).
Given the complexity and chronicity of this population; it is important that the clinician
treating the painful symptoms also involve these specialists to manage the ongoing and
concurrent psychological issues that exist or continue beyond the initial evaluation and
treatment period (Arteta et al., 2016). If the clinician feels appropriate, the management
can be concurrent and effective.
Culture plays a very important role in the treatment of chronic pain, especially
when opioid analgesics are being considered. The clinician has a unique role in
identifying, assessing and maintaining cultural influence that may create barriers for the
patient and treating clinician. It is well established in the literature that culture influences
both the expression and perception of pain is certain populations, making the
identification imperative during the initial assessment period. Some very basic
assessment components should be evaluated during this period. They include (Arteta et
al., 2016):
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A. Family and affiliation systems
1. Family system structure (nuclear or extended)
2.

Role definition (each family member’s individual role in the family)

B. Social Patterns
1. Daily routine (social functions)
2. Nutritional considerations (dietary patterns-individual and family)
C. Language and family traditions
1. Current language spoken
2. Verbal and nonverbal communication techniques
3.

Major cultural traditions
D. Religion
1. Religion beliefs and current practices
2. Health Practices and religion’s role
E. Health practices and health beliefs
1. Health and illness attitude
2. Health Care decision makers
3. Define any remedies, folk medicine, rituals and healers

Cultural assessment is imperative to have a complete evaluation of the patient
suffering chronic pain. Opioid analgesics are considered taboo is some cultural settings
and early identification is crucial to ensure an appropriate treatment planning occurs
(IOM, 2011). Again, the clinician should use personal judgment when determining the
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assessment needed for their individual patients, however these basic concepts should be
considered.
Risk Assessment and Risk Tools
Risk assessments imperative in the treatment of patients suffering chronic
noncancerous pain when opioids are being considered (Kulich & Stone, 2012). This
assessment provides a means of applying a risk level to each patient and allows the
clinician the opportunity to tailor monitoring techniques to each treatment plan. Each
clinician should determine which assessment technique and tool suits their patient
population best. The current guidelines identify patients into three risk categories
including low risk, medium risk and high right. These categories, regardless of screening
tool use, should be used and the criteria should be assessed. Below are the current criteria
for each classification.

Low risk classification

Medium risk classification

High risk classification

Known pathological pain processes
with objective findings

Known pain pathology with
subjective and objective
findings, but no more than
three painful areas
Confirmed diagnostic
evidence of pain pathology

Unknown pain pathology
with subjective
complaints and no

Clinical correlation with available
testing (MRI, EMG), physical
examination and diagnostic
interventional procedures (facet
blocks, nerve root block)
Limited psychological comorbidity

No personal or family history of
alcohol or prescription drug abuse

Moderate psychological and
comorbidities that are
controlled by medical
treatment
Personal and family history
of alcohol or prescription
drug abuse

objective findings
Pain in more than three
body regions

Abnormal drug behaviors
(multiple request)

Major or untreated
medical and psychological
conditions
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Well –defined coping strategies

Age of >45 years

Agreeable and willing to
participate in interventional
and multimodality
approaches to treatment
Attempting to perform
activities of daily living and
normal daily function

despite pain
Agreeable and willingness to
participate in interventional pain
treatments

Age < 45

Minimal or no coping
strategies with
magnification of
symptoms
Unwilling or refusal of
available interventional
modalities

Risk Assessment Tools
The opioid risk tool (ORT), as explained by Kulich and Stone (2012), is a selfreporting, five-item assessment tool that helps predict the potential for uncharacteristic
drug-related behaviors Scoring is simple and practical in the clinical setting (Kulich &
Stone, 2012). Scoring can be completed within minutes and typically occurs during the
initial assessment period. Content areas include personal and family history of drug abuse
including illicit drugs, alcohol use and prescription drug history (Kulich & Stone, 2012).
Other scored items include current age, history of preadolescent sexual abuse and
psychological diseases (Kulich & Stone, 2012). Each of these items are given a numeric
value and totaled at the end of the assessment. Scores at 3 and below represents a low risk
of opioid abuse, while a score of 4 to 7 represent moderate risk and a score of 8 or higher
represents a much higher risk level (Kulich & Stone, 2012).
The Screener and Opioid Assessment for Patients is another comprehensive selfreporting tool for any patient being considered for long-term opioid therapy (Kulich &
Stone, 2012). This 24-item screening is used to predict potential aberrant behaviors
(Kulich & Stone, 2012). The content is geared toward identify factors that are correlated
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with the misuse and abuse of opioid analgesics such as alcohol abuse, substance abuse,
cravings and mood. Scoring is completed at the time of the assessment and any patient
receiving a score of 18 or more are considered high risk (Kulich & Stone, 2012). In fact,
this assessment is accurate in 90% of the population when determining the eventual
misuse of opioid analgesics (Kulich & Stone, 2012). This screening tool has been
validated in several literature sources and cross validated in over 600 patients throughout
the United States (Kulich & Stone, 2012).
Conversely, the Diagnosis, Intractability, Risk and Efficacy (DIRE) rating tool is
comparable to the ORT, however it is a clinician-rating tool. It is used to predict
compliance and appropriateness in patients that require long-term opioids in less than
seven minutes (Belgrade, Schamber & Lindgren, 2006). The content consists of questions
that explore diagnosis, patient care involvement, psychological history, dependability,
social support and previous opioid drug efficacy (Belgrade et al., 2006). Scoring from 7
to 13 would represent a candidate that is not suitable for long-term opioids and scores
ranging from 14-21 would be more appropriate for the long-term use of opioids
(Belgrade et al., 2006).
The final screening tool that has been used in chronic pain and serves an
important role in evaluating patient for chronic opioid therapy is the CAGE-Aid. This
screening tools original design was primarily for alcohol use, however the redesign
format adds question about drug abuse to the questioning set (Kulich & Stone, 2012).
This screening is easy to perform and takes little time to administer. The content consist
of 4 pointed questions following the acronym:
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C Have you ever felt that you ought to cut down on your drinking or drug use?
A Have people annoyed you by criticizing your drinking or drug use?
G Have you ever felt bad or guilty about your drinking or drug use?
E Have you ever had a drink or used drugs first thing in the morning to steady
your nerves or to get rid of a hangover?
Answer of two or more yes answer is considered positive and extreme caution
should be taken with this patient population (Kulich & Stone, 2012). There is current
literature that suggests that the positive screening should be considered with one yes
answer to the screening (Kulich & Stone, 2012). This is still being considered and the
current recommendation remains at two yes responses. Clinicians should use preference
while remaining consistent when administering this screening (Kulich & Stone, 2012).
An example of each risk assessment tool is available at
http://www.aafp.org/fpm/toolBox/viewToolBox.htm
Patient Monitoring and Compliance
Patient suffering CPSs that do not have an underlining cancerous process require
regular monitoring and follow up care when opioid are being used as a part of the
treatment plans. The current guidelines identify several helpful monitoring strategies that
should be implemented by clinicians prescribing opioids or considering them in their
treatment plans (Haffajee, Jena & Weiner, 2015).
Urine Toxicology
Urine toxicology screening is vital for the identification of the potential
unauthorized use of prescription and illicit drugs, diversion and non-compliance

79
(Haffajee et al., 2015). There are several types of urine drug testing that can be used in
practice and the least complex and basic is immunoassay testing (Haffajee et al., 2015).
This test provides a belief overview that can be easily administered in the clinical setting,
however it fails to quantify the result. It also limits the testing to positive and negative
results and doesn’t provide specific drug information. In recent studies the use of gas
chromatography/mass spectrometry urine toxicology has proven to be the most effective
way to quantify the extent of current drug usage, both prescription and illicit (Haffajee et
al., 2015). Additionally, the use of gas chromatography/mass spectrometry can provide
values related to drug metabolites, which is particularly important to avoid alteration of
the testing (Haffajee et al., 2015). It is imperative that clinicians become familiar with the
common drug and metabolite pathways to ensure accurate interpretation (See appendix
A)(Haffajee et al., 2015). Misunderstandings can occur since the metabolites may be
different then the parent drug (Haffajee et al., 2015). Patients that are prescribed
hydrocodone may show positive for oxycodone or hydromorphone and clinicians may
discontinue the patient’s medications without cause (Haffajee et al., 2015).
Current guidelines offered by the CDC recommended that urine screening be
completed prior to the initiation of opioid analgesics and at minimal annually (Dowell et
al., 2016). In patients that are identified as medium or high risk, testing should be
completed every three months or monthly should the clinician feel appropriate (Dowell et
al., 2016). Random testing is also essential when performing urine screening. Random
testing should be completed in all risk categories, however should occur more frequently
on populations falling in the medium and high-risk categories (Dowell et al., 2016).
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Opioid Agreements
Opioid agreements play a vital role in the relationship between patient and
provider, particularly when opioids analgesics are a part of the treatment plans. The
AAMP and CDC guidelines recommend opioid agreements be completed prior to the
initiation of opioids for all patients (Dowell et al., 2016; Chou et al., 2009; Payne et al.,
2010). These agreements should contain specific information regarding the clinician’s
expectations of the patient while receiving opioid analgesics (see appendix B) Basic
opioid agreements should include the following (Payne et al., 2010):
•

Patient and clinician’s responsibilities

•

Overall treatment and function goals.

•

Risk and benefits of opioid analgesics

•

Filling and refilling expectations and requirements

•

Specific information regarding early refills, emergency appointments and missed
appointments.

•

Criteria for discharge from practice
The opioid agreement should be read and signed by the patient or representative,

clinician and witness (Payne et al., 2010). Once the initial agreement is signed it should
be kept in the patient chart for reference (Payne et al., 2010). A copy should be provided
to the patient after the signature is obtained (Payne et al., 2010). The agreement and
signatures should be updated yearly to ensure the patient is up-to-date with any changes
that may occur.
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Pill Counting
Pill counting can be an easy and effective means of avoiding diversion, while
increasing compliance This process requires the patient to bring their prescribed
medications into the office for a physical count, usually by a licensed professional.
Clinicians should consider developing a relationship with pharmacies that have
experience with opioid analgesics and offer bubble packing of all opioid analgesics. This
package method prevents the possibility of patients buying medications identical to those
being prescribed or altering the pill bottles prior to counting. Typically, the process
would be done at random, but in patients with a classification of medium to high risk it is
recommended that they bring their pills to every scheduled visit. For random testing, the
clinician must set an expected timeframe for which the patient must show up to prevent
an extended period of time passing after initiating the call for random testing. Usually
this ranges from 12 to 24 hours. There is specific documentation that should occur when
a pill count is conducted. This would include documentation of the time, date, number of
pills, person or persons conducting the count and any inconsistencies. This
documentation should reflect any action taken as a result of the count. Patient should be
made aware that this is a part of their treatment and is a requirement in order to receive
ongoing prescriptions.
Prescription Drug Monitoring Programs
The use of prescription drug monitoring programs is gaining traction nationally. It
is estimated that 49 states have either a monitoring program in place or legislation
supporting the use of these programs (Haffajee et al., 2015). These monitoring programs

82
are designed to assist the clinician with monitoring the filling and dispensing of opioid
analgesics for each patient they are considering for long-term opioid management
(Haffajee et al., 2015). The purpose is to identify patients that may be filling multiple
prescriptions with multiple providers. Each state differs in regards to the information that
is collected and stored in the respective database. Some basic information is collected
throughout most states (Haffajee et al., 2015). Here are some examples of collected data
•

Patient demographic (Name, date of birth, address, phone number and gender)

•

Prescriber Information (Clinician name, address and phone number and DEA
number)

•

Detailed Medication Information (Dose, frequency, date written and filled)

•

Pharmacy Information (Pharmacy name, address and phone number) (Haffajee et
al., 2015, p.122):
The AAMP and CDC recommend that clinicians review and document the

patients opioid prescribing record prior to the initiation of any opioid treatment (Dowell
et al., 2016; Chou et al., 2009; Payne et al., 2010). Additionally, it is recommended that
an updated report be reviewed every 3 months during treatment (Dowell et al., 2016;
Chou et al., 2009; Payne et al., 2010). In patients that are identified as medium and high
risk reports should be reviewed monthly (Dowell et al., 2016; Chou et al., 2009; Payne et
al., 2010). Any discrepancy should be documented and include any action that may be
taken.
The monitoring of patients being considered for opioid therapy for chronic pain is
an imperative part of ensuring compliance (Dowell et al., 2016; Chou et al., 2009; Payne
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et al., 2010). Clinicians and providers should identify the most useful means of
monitoring for their practice, however it is strongly recommended in the literature that
monitoring should include more than one monitoring technique (Dowell et al., 2016;
Chou et al., 2009; Payne et al., 2010). Documentation is a crucial part of this process and
clinicians should develop policies to ensure all staff is compliment with the monitoring
process (Chou et al., 2009).
Opioid Initiation/Escalating and Discontinuation
Initiating opioid analgesics
The initiation of opioid analgesics should only occur once a definitive diagnosis
and pathology is established and nonpharmacologic therapy is exhausted (Chou et al.,
2009; Dowell et al., 2016). A complete risk assessment should be performed and all
benefits should be clearly stated. Therapy goals should be developed and all expected
functional improvements should be outlined prior to the initiation of opioids. The use of
nonpharmacologic therapies such as epidural injections, nerve root blocks, facet
injections physical therapy and chiropractic care should be considered and implemented
prior to the consideration of opioid analgesics (Chou et al., 2009; Dowell et al., 2016).
Additionally, the use of non-opioid medications including acetaminophen, nonsteroidal
inflammatory drugs should be considered if no contraindication exists (Chou et al., 2009;
Dowell et al., 2016). The AAPM (appendix C) and CDC (appendix D) developed
guidelines that focus on the initiation and titration of opioids (Chou et al., 2009; Dowell
et al., 2016). All clinicians considering opioid analgesic for their patients should observe
these guidelines.
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The initiation of opioid analgesics for chronic non-cancer pain symptoms should
be treated as a short-term trial, which can last for as short as a few weeks and last for a
few months (Chou et al., 2009; Dowell et al., 2016). Initially the use of short-acting
opioids (SA) /immediate release (IR) (see appendix E), which includes formulations such
as Hydrocodone, Oxycodone and Oxymorphone, should be used in the opioid-naïve
patient (Chou et al., 2009; Dowell et al., 2016). The shorter half-life lessens the risk of
overdose during the initial phases. The lowest available dose should be used in all
populations (Brown, Swiggart, Dewey, & Ghulyan, 2012). The rapid onset (10-60 mins)
and short duration (2-4hrs) is best for acute and short-term pain pathologies (Chou et al.,
2009; Dowell et al., 2016). The clinician should reassess the patient’s response in 4
weeks or sooner depending on the individual clinician’s comfort level with the patient
and their current health state (Brown et al., 2012). Examination and documentation
should reflect the patient’s response, any side effects/adverse reactions, functional
improvements and any therapeutic goals that may have been met. No opioids should be
started without an adequate exit strategy, should the risk outweigh the benefit at anytime
during treatment (Brown et al., 2012). The evidence and guidelines recommend a
minimal waiting period of five half lives before any titration occurs to get a reasonable
assessment of the previous doses effect. The clinician should use extreme caution when
initiating SA/IR opioids in patients >65 years of age and patients with renal and hepatic
dysfunction to avoid the possibility of overdose/death (Chou et al., 2009; Dowell et al.,
2016). This opioid preparation is not to be used as a long-term option and should be
reserved for pain that is acute in nature, intermitted and expected to resolve within 3
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months (Chou et al., 2009; Dowell et al., 2016). Using these medications for extended
periods has been known to produce extended tolerance, abuse and higher incidence of
addiction (Brown et al., 2012).
In contrast the use of extended release (ER) or long-acting (LA) version of these
medications should only be considered in patients that have previous exposure to the IR
version and now require around the clock dosing. Patients that continue to suffer pain
beyond a 3-month period should be considered for the ER/LA version of opioid treatment
(Chou et al., 2009; Dowell et al., 2016). The literature demonstrates a reduced incidence
of tolerance, abuse and addiction in this patient population. This ER/LA class of
medication includes drug such as OxyContin, Ms Contin, Duragesic and Oxymorphone
ER (see appendix F). It is imperative to observe and understand the pharmacological
properties of these medications before considering them for patients suffering chronic
non-cancer pain symptoms (see appendix F). The onset of LA/ER medications is
comparatively longer at 30-120 min and the duration is between 7-72hrs when compared
to the IR/SA version (Chou et al., 2009; Dowell et al., 2016). The use of these
medications should only be initiated when the pain is clearly defined and considered
severe and long term (Chou et al., 2009; Dowell et al., 2016). The chronicity of the pain
symptoms must be clearly documented before the initiating these medications.
Reevaluation must occur within the first 3 weeks of initial dosing and the patient must be
given adequate time on the medications before making a decision to titrate dosing. This
may require additional time beyond the initial follow up period and the clinician should
not prematurely adjust dosing.
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Dose titration and escalation
The process of opioid analgesic titration requires vigilance and careful
consideration to avoid adverse patient outcomes. Failure to be vigilant and careful in this
process has led to serious and unnecessary sequela for patient receiving these medications
(Brown et al., 2012). The literature demonstrates a clear link with dose and titration
related overdose (Brown et al., 2012). The CDC identifies an increase risk in populations
titrated to >90 morphine milligram equivalents (MME) a day (Dowell et al., 2016).
Specifically, the risk factors increased by 1.9 to 4.6 percent in doses >20 MME day and
2.0-8.9 in patient receiving >100 MME a day (Dowell et al., 2016). Therefore, the safest
dosing recommendation is <50 MME a day and the risk is drastically reduced in this
population (Dowell et al., 2016). The current literature also demonstrated that doses <50
not only increased the risk of negative patient outcomes, but also did not show clinical
benefit (Dowell et al., 2016). Any clinician exceeding the recommended <50 MME
should clearly document the need to adjust beyond this clinical recommendation (Dowell
et al., 2016). Each clinician should take into account the patients diagnosis and functional
improvements as it relates to the risk once the titration exceeds the clinical
recommendation. Any patient receiving opioids at or above the clinical recommendation
should consider increasing the observation of the patient, increasing the amount of urine
drug screening and making the appropriate referrals to pain management (Dowell et al.,
2016). The clinician should also consider prescription Naloxone (Narcan) for the patient
for any dose exceeding the clinical recommendation. It is imperative for the clinician to
be familiar with their current state regulations regarding the care of patients receiving
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opioids. In some states once a patient reaches levels beyond the recommended threshold
referral must occur or the clinician is in violation of state law and is subject to
disciplinary action.
Continuous titration and escalation of opioid analgesic is not recommended and is
strongly discouraged in the guidelines offered by both the CDC and AAPM (Chou et al.,
2009; Dowell et al., 2016). Patients that do not receive adequate relief >50% from opioid
analgesic of >50 MME should consider alternative treatments and consideration should
be given to performing a drug holiday (Chou et al., 2009; Dowell et al., 2016). This
process would include a complete cessation of opioid use and allowing the mu receptors
an opportunity to regenerate to pre-opioid status. If the receptors are unresponsive it is
unlikely that any additional titration of the opioid would be beneficial and further damage
may occur. Additionally, it is important to have a clear understanding of paradoxical
hyperalgesia when escalation and titration is failing (Chou et al., 2009; Dowell et al.,
2016). This condition occurs when the mu receptors are over used and overestimated by
the chronic and continuous use of opioid analgesics. Continuous titration and escalation
of doses should alert the clinician to the possibility of this phenomena and appropriate
action should be implemented (Chou et al., 2009; Dowell et al., 2016). Typically, this
would require a cessation or rotation of all opioid analgesics for a period of 3 months.
Discontinuation of Opioid Therapy
The discontinuation of opioid therapy should occur if aberrant drug behavior is
noted, diversion is occurring, side effect/adverse reaction develop and when there is
minimal clinical or functional improvements seen (Chou et al., 2009; Dowell et al.,
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2016). The initial tapering of opioids should be slow and can be as little as 10% per
week, however a more aggressive taper can occur at a rate of 25% to 50% every week
(Chou et al., 2009; Dowell et al., 2016). The clinician should account for withdraw
symptoms should the taper be aggressive. Pre-planning and patient education is
imperative during this process. The patient should be instructed that withdraw may occur
and should be made aware of the signs and symptoms. Depending on the patients dosing,
referral may be needed to an addiction or opioid rehabilitation specialist (Brown et al.,
2012). It is imperative the clinician recognize that a failure to properly taper a patient
receiving opioid analgesics can lead to civil and licensure penalties. Abandonment of the
patient can be implied if the proper steps are not taken and proper discontinuation occurs
(Brown et al., 2012).
Patient Education
Patient education is an imperative process in the prescribing and maintain of opioid
analgesics. The process will require the clinician to identify any barriers that may exist
prior to the development and structuring of the education. This would include any
language, educational and cognitive issues the patient demonstrates. Clinicians will need
to individualize the materials to ensure the education is conveyed in an appropriate
context. In any case, a few very important points should be addressed with each patient.
The following are key components that should be addressed (Brown et al., 2012):
1. Patients should be instructed to review all prescription packaging and contact
the provider if label is incorrect.
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2. Ensure all prescriptions are not expired and never use medications beyond the
expiration date.
3. Instruct the patient that they should never use alcohol or sedatives while on
opioid analgesics.
4. Never alter the tablets including crushing, breaking or chewing, especially
with ER/LA preparations.
5. Never share or provide medications to others including family or friends.
Safe Disposal and Storage
Patients need to be adequately trained on the proper storage and disposal of opioid
analgesics (Brown et al., 2012). Proper storage should be in a locked and secure location
with only very few that has access to the secured place. They should be out of the reach
of children and pets at all times (Brown et al., 2012). Patient should be instructed that
they should never be left in a motor vehicle or unsecure location even for a short period
of time (Brown et al., 2012). If disposal is needed each state has specific laws regarding
disposal and clinicians should become familiar with their individual states guidelines for
disposal (Brown et al., 2012). There is some commonly used method of disposal
including returning to the pharmacy, returning to the physician’s office and flushing
down the toilet (Brown et al., 2012). Additionally, several police and fire departments
offer take-back programs which patients can take advantage of locally. Patients can
contact their local municipalities for additional information regarding these take-back
programs. Safe disposal and storage is an essential part of prescribing opioid and
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clinicians need to be aware of all the resources patients have at their disposal (Brown et
al., 2012):
Naloxone Prescribing
The use of take home Naloxone, an opioid antagonist, has been gaining a
significant amount of national exposure within recent years. The increase in prescription
drug overdose related deaths have reached an all-time high (Dowell et al., 2016). From
2000-2014 over 500,000 deaths have occurred and this number continues to grow yearly.
Interventions must be considered when opioids are being used as a part of a treatment
plan for patient suffering chronic pain (Dowell et al., 2016). Most recently, Evzio
(Naloxone) was approved by the Federal Drug Administration for the use in the home by
non-licensed caregivers (Dowell et al., 2016). This hand-held auto-injectable device is
easy to use and delivers pre-set dosing that can reverse an overdose situation before first
responders arrive (Dowell et al., 2016). Patients receiving any opioid exceeding >90
MME should be considered a high risk for overdose and consideration must be given for
take home Naloxone (Dowell et al., 2016). There are a few other delivery systems
including intranasal which are slowly making their way to the market. Federal, state and
local community leaders are developing programs designed to assist caregivers and
family members with the tools and training needed to prevent overdose and death in the
home (Dowell et al., 2016).
Conclusion
The use of opioid analgesic may be necessary in the treatment of chronic noncancer pain and clinicians need to have a detailed understanding of the current guidelines.
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This continuing educational module provides an overview of the current and most recent
up-to-date guidelines and recommendations for the assessment, examination, dosing,
monitoring and patient education needed to ensure a safe, efficient and effective care.
Clinicians need to strike a balance between safe and effective care and the potential harm
that opioid pose to the patient and society as a whole. This educational module will assist
in the development and implementation safe and effective policies to guide the clinician
in any setting.
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Appendix C: ER/LA Opioid Analgesics

ER/LA Opioid Analgesics
MS Contin (Morphine Sulfate ER tablets)

Duragesic (fentanyl transdermal

system)
Opana ER (Oxymorphone HCI ER tablets)

Butrans (buprenorphine transdermal

system)
OxyContin (Oxycodone HCI ER tablets)

Zohydro ER (hydromorphone HCI ER

capsule)
Exalgo (Hydromorphone HCI ER tablets)

Nucynta ER (tapentadol HCI ER

tablets)
Avinza (morphine sulfate ER capsule)
Hysingla ER (hydrocodone ER tablets)

MS Contin/Avinza

Morphine Sulfate ER Tablets

Dosing Preparations
Dosing Frequency
Current Guidelines

15 mg, 30 mg, 60 mg 100 mg 200 mg
Every 8 or Every 12 Hours
• Start at lowest dose of 15 mg and
titrate to maximum effectiveness
without side effect
• Not to be used in opioid naïve
patients
• Titration to occur only after 1-2
week period
• <50 MME daily dosing
recommended

Pharmacology

Morphine Sulfate binds to opioid
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receptors (mu) producing analgesic.
Metabolism occurs in the liver and GI
tract with 10-20% bioavailability.
Excretion is primary urine (85%)
with half life of 2-4hrs
Opana ER
Dosing Preparations

Dosing Frequency
Current Guidelines

Pharmacology

Oxymorphone HCI ER tablets
5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg,
30 mg,
40 mg
Every 12 Hours
Opioid naïve patients should be
started at 5 mg every 12 hrs
Avoid usage in patients with impaired
hepatic/renal function.
(CrCl<50ml/min)
Titrate by 5-10 mg with a minimal of
3-7 days between titrations
Avoid alcohol: Increases
oxymorphone levels leading to fetal
overdose
Oxymorphone (semi-synthetic) is an
opioid that exerts its affect in the
central nervous system. Binds with
mu-receptors and inhibits GABA
altering the descending pain pathway.
There is direct action at the level of
the brain stem, which can lead to
respiratory depression.
Half-life 7.3-11.3 hrs respectively.
Metabolizes though the hepatic
system while excretion via urine and
feces.

OxyContin

Oxycodone HCI tablets

Dosing Preparations

10 mg, 15 mg, 20 mg, 30 mg, 40 mg,
60 mg, 80 mg

Dosing Frequency

Every 12 Hours
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Current Guidelines

Opioid naïve patients should be
started at 10 mg every 12 hrs
Avoid usage in patients with impaired
hepatic/renal function.
(CrCl<50ml/min)
Titrate by 5-10 mg with a minimal of
1-2 days between titrations
40 mg, 60mg and 80mg to be
reserved for Opioid-tolerant patients.
OxyContin binds to opioid receptors
(mu) producing analgesic. About
60% to 87% of an oral dose of
OxyContin reaches the central
compartment in comparison to a
parenteral dose. This high oral
bioavailability is due to low presystemic and/or first-pass
metabolism. Primarily metabolized in
the liver and excreted via urine. Halflife 4.5 hrs.

Pharmacology

Exalgo

Hydromorphone HCI ER tablets

Dosing Preparations

8 mg, 12 mg, 16 mg, 32 mg

Dosing Frequency
Current Guidelines

Once Daily
All dosing should to be reserved for
Opioid-tolerant patients only
Renal impairment (moderate): 50%
normal starting dose
Renal impairment (severe): 25%
normal starting dose
Hepatic impairment (all levels) 25%
normal starting dose.
Titrate by 4 mg with a minimal of 3-4
days between changes.
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Pharmacology

Binds to a variety of opioid receptors
including mu and k-receptors.
Metabolized in the liver and plasma
levels gradually increase over 6 to 8
hours, and subsequently
concentrations are maintained for
approximately 18 to 24 hours postdose. Excretion occurs in the urine
(75%) and feces (1%). Half-life
11hrs, 40 hrs with renal impairment.

Hysingla ER/Zohydro ER
Dosing Preparations

Hydrocodone ER tablets
Hysingla ER: 20 mg, 30 mg, 40 mg,
60 mg, 80 mg, 100 mg, 120 mg.
Zohydro ER: 10 mg, 15 mg, 20 mg,
30 mg, 40 mg 50 mg

Dosing Frequency

Hysingla ER :Once Daily
Zohydro ER: Every 12 hours
• Non-tolerant patients starting dose
20 mg for Hysingla and 10 mg for
Zohydro
• Titrate 10 mg at single time with
minimal of 3 days between
titrations.
• 50% normal starting dose with
hepatic and renal impairment
• 80 mg, 100mg, 120 mg reserved
for opioid-tolerant patients
population only
• Monitor for QTc prolongation on
EKG (Hysingla)

Current Guidelines

Pharmacology

Binds to a variety of opioid
receptors including mu and kreceptors. Metabolized in the liver
active metabolite (hydromorphone).
Excreted in the urine with a half-life
of 7-9 hrs
Butrans

Buprenorphine Transdermal System
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Dosing Preparations

5 mcg/hr., 7.5 mcg/hr., 10mcg/hr., 15
mcg/hr., 20 mcg/hr.

Dosing Frequency
Current Guidelines

Every 7 days
• Initial dosing for non-tolerant
patient should be 5 mcg/hr.
• Titration should occur by 5 mcg/hr
with a minimal 72-hour
• Maximum daily dosing: 20 mcg/hr.
(risk of QTc prolongation in higher
doses)
• Avoid exposure to heat or activities
that increase body temperature.
• Observe for hepatotoxicity (liver
function testing should be
performed every 3 months)
Butrans produces agonism at delta
receptors, partial agonism at the mu
receptors and antagonism at the kreceptors. Primary metabolism occurs
in the liver with a half-life of 26hrs.

Pharmacology

Duragesic
Dosing Preparations

Dosing Frequency
Current Guidelines

Pharmacology

Fentanyl Transdermal System
12 mcg/hr., 25 mcg/hr., 37.5 mcg/hr.
50 mcg/hr., 62.5 mcg/hr., 75 mcg/hr.,
87.5 mcg/hr., 100 mcg/hr.
Every 72 hours
• Lowest possible starting dose
should be considered (12.5 mcg)
• Not to be used as a first line
therapy and all strengths should be
used in patients that have prior
exposure high dose opioids
• Avoid in hepatic and renal function
• Avoid exposure to heat or activities
that increase body temperature.
Binds to primary mu receptors with
little affinity to k-receptors. Primarily
metabolized in the liver and excreted
in urine and feces. 17 hour half-life
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Nucynta ER

Tapentadol ER tablets

Dosing Preparations

50 mg, 100 mg, 150 mg, 200 mg 250
mg

Dosing Frequency
Current Guidelines

Every 12 hours
• Opioid naïve patients should be
started on 50 mg every 12 hrs
• Titrate by 50 mg with a minimal of
3 days between increases
• Contraindicated with MAOI
therapy
• Avoid usage in hepatic and renal
impairment (max 100 mg once
daily)
Nucynta ER attaches to mu-opioid
receptor and inhibit reuptake of
norepinephrine (central opioid
agonist). Primarily metabolized in the
liver with excretion occurring in the
urine. Half-life: 4-5 hrs

Pharmacology
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Appendix D: IR/SA Opioid Analgesics

IR/SA Opioid Analgesics
Hydrocodone/acetaminophen (Hycet, Lortab, Norco, Vicodin, Xodol)
Hydromorphone (Dilaudid)
Morphine (MS IR)
Oxycodone (Oxy IR, Roxicodone)
Oxycodone/acetaminophen (Endocet, Percocet, Roxicet)
Oxymorphone (Opana IR)
Tapentadol (Nucynta IR)

Hydrocodone/acetaminophen
Dosing Preparations

Dosing Frequency
Current Guidelines

Hycet, Lortab, Norco, Vicodin,
Xodol
2.5 mg/325 mg, 5 mg/325 mg, 5
mg/300 mg 7.5 mg/300 mg, 7.5
mg/325 mg, 10 mg/300 mg, 10
mg/325 mg
Every 4-6 hours as needed
• Use in acute pain and initial
opioid trial only
• >3 months: consider long-acting
• Hepatic function testing every 3
months
• Limit daily amount due to
acetaminophen intake (4000 mg
acetaminophen/day)
• Observe and monitor for
hepatotoxicity
• Caution in hepatic function
impairment.
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Pharmacology

Activates mu-receptors in the central
nervous system. Onset is typically
10-20 mins with peak effects in 3060 mins. Metabolized in the liver
extensively. Excreted in the urine
with a half-life of 3.8-4.9 hrs.

Hydromorphone

Dilaudid

Dosing Preparations

2 mg, 4 mg, 8 mg

Dosing Frequency
Current Guidelines

Every 4-6 hrs as needed
• Opioid naïve patients should be
started on 2-4 mg
• Caution in elderly and debilitated
patients. (Consider lowest dose).

Pharmacology

Hydromorphone interacts with mureceptors with a lower affinity for
kappa-receptors.
Primary effects occur in the central
nervous system
Derivative of morphine with better
absorption.
Metabolized in the liver and excreted
in the urine Half-life 2.6 hours.
Morphine

Morphine IR

Dosing Preparations

15 mg, 30 mg

Dosing Frequency
Current Guidelines

Every 6 hours as needed
• Opioid naïve patients initial dosing
10-30 mg every 6hrs
• Caution in elderly and debilitated
patients
• Max dosing>50 daily
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Pharmacology

Morphine Sulfate binds to opioid
receptors (mu) producing analgesic.
Metabolism occurs in the liver and GI
tract with 10-20% bioavailability.
Excretion is primary urine (85%)
with half life of 2-4hrs
Oxycodone

OxyIR, Roxicodone

Dosing Preparations

5 mg, 10 mg, 15 mg, 20 mg, 30 mg

Dosing Frequency
Current Guidelines

Every 4-6 hrs as needed
• Opioid naïve patients initial dosing
5-10 mg every 4-6hrs
• Avoid the use of 20 mg and 30 mg
tablets in all patient populations
(consider ER version)
• Usage beyond 3 months need
reevaluated for ER version
• Caution in patients <30 years of
age and >50 years of age.
Oxycodone primarily affects mureceptors with a weaker affinity for
kappa and delta receptors, working in
the central nervous system.
Semisynthetic opiate with derivatives
of hydrocodone and morphine.
Primarily metabolized in the liver and
excreted in the urine. Well absorbed
with bioavailability of 60-87%
Half-life 4.5 hrs

Pharmacology

Oxycodone/acetaminophen
Dosing Preparations

Dosing Frequency
Current Guidelines

Endocet, Percocet, Roxicet
2.5 mg/325 mg, 5 mg/325 mg, 7.5
mg/300 mg, 7.5 mg/325 mg, 10
mg/325 mg
Every 4-6 hrs as needed
• Opioid naïve patients initial dosing
5-10 mg every 4-6hrs
• Hepatic function testing every 3
months
• Limit daily amount due to
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acetaminophen intake (4000 mg
acetaminophen/day)
• Observe and monitor for
hepatotoxicity
• Caution in hepatic function
impairment
Oxycodone primarily affects mureceptors with a weaker affinity for
kappa and delta receptors, working in
the central nervous system.
Semisynthetic opiate with derivatives
of hydrocodone and morphine.
Primarily metabolized in the liver and
excreted in the urine.
Half-life 4.5 hrs

Pharmacology

Oxymorphone

Opana IR

Dosing Preparations

5 mg, 10 mg

Dosing Frequency
Current Guidelines

Every 4-6 hrs as needed
• Opioid naïve patients initial dosing
5-10 mg every 4-6hrs
• Avoid usage in patients with
impaired hepatic/renal function.
(CrCl<50ml/min)
• Titrate by 5-10 mg with a minimal
of 3-7 days between titrations
• Avoid alcohol: Increases
oxymorphone levels leading to
fetal overdose
Oxymorphone (semi-synthetic) is an
opioid that exerts its affect in the
central nervous system. Binds with
mu-receptors and inhibits GABA
altering the descending pain pathway.
There is direct action at the level of
the brain stem, which can lead to
respiratory depression.
Half-life 4.5 hrs. Metabolizes though
the hepatic system while excretion
via urine and feces.

Pharmacology
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Tapentadol

Nucynta

Dosing Preparations

50 mg, 75 mg 100 mg

Dosing Frequency
Current Guidelines

Every 4-6 hrs as needed
• Opioid naïve patients initial dosing
50-75 mg every 4-6hrs
• Avoid usage in patients with
impaired hepatic/renal function.
(CrCl<50ml/min)
• Titrate by 5-10 mg with a minimal
of 3-7 days between titrations
• Max daily dosing: 600 mg total
• Avoid alcohol: Increases
oxymorphone levels leading to
fetal overdose
Tapentadol attaches to mu-opioid
receptor and inhibit reuptake of
norepinephrine (central opioid
agonist). Primarily metabolized in the
liver with excretion occurring in the
urine. Half-life: 4-5 hrs

Pharmacology
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Appendix E: Common Drug and Metabolite Pathways
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Appendix F: Opioid Agreement Example
Opioid Agreement
• I understand that the treatment I receive by the (Name of Service) includes opioid
and/or sedative medications. I also agree to the following while receiving these
medications:
• I understand that the goals of my treatment with medications are to increase my
activities at home and/or work a decreased my pain symptoms and behavior
within the time specified in my treatment plan.
• I understand that opioid medications are only one part of my therapy and agree to
follow all parts of my treatment program (ex. Physical therapy, behavioral pain
management, etc) and office appointments.
• I will not obtain any opioid or sedative medications from any source other than
the (Name of Service). In the event of an emergency that requires treatment with
opioid or sedative medications, I will notify a staff member at (Name of Service)
the following business day.
• (Name of Service) requires that all opioid or sedative medications prescribed for
me by the Center must be filled by the following pharmacy:
_________________________
• If I do not agree to this provision, I have been informed that the Center may not
write for opioid or sedative medications and this may constitute termination of
my patient status at the Center.
•

In the event that I am prescribed opioid or sedative medications by another
physician, I understand that I must notify the (Name of Service) within 24 hours.

•

I understand that lost or stolen medications and/or prescriptions will not be
replaced under any circumstance Any adjustments to my medications will
be initiated by the (Name of Service).

•

No increase in medication doses should be made without the approval of the
prescribing physician.

•

I understand that I must provide at least 7 business days for ALL refills. No
prescriptions will be refilled early under any circumstance. If you are going out of
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town, arrangements will be made for delivery of your medication I will call the
pharmacy with any questions about DELIVERY of my medication.
•

I will call the pharmacy and notify them myself of any address or phone number
changes before my refill.

•

No opioid medications will be adjusted over the phone. I will not call the
pharmacy or the Pain Center requesting more medication. If needed, I will call the
Clinic for a follow up appointment or go to the nearest emergency room.

•

I will make/attend follow up appointments at the specified day/time. If I do not
show for 3 or more appointments, I may be discharged from the Pain Center.

•

I understand that I must provide pills for random pill counts and/or provide urine
for random urinalysis upon physician request. This urine screen must be done
within 24 hours, unless otherwise specified by the physician or nurse. Failure to
provide the urine screen within the specified amount of time may result in
discharge from the clinic.

•

I understand that if results of my urine screen indicate the use of alcohol, illicit
drugs of any kind, or narcotics not prescribed by the (Name of Service), this will
result in my immediate discharge from the Center.

•

I understand that failure to follow these guidelines may require cessation of opioid
and/or sedative therapy, referral to a substance abuse specialist, and possible
termination of my patient status at the (Name of Service).

•

I understand that other physicians involved in my medical care will be notified of
my discharge from the (Name of Service).

•

I understand that unruly behavior is not tolerated, and it is grounds for immediate
discharge.

•

I understand that I am not to remove medications from the bubble pack until the
time when it is necessary to take them. I understand that I should count my
medication when I receive it from the pharmacy and notify the pharmacy and
(Name of Service) if it is not what it should be.

•

CAUTION: Opioid medications may cause drowsiness. Alcohol should not be
consumed while taking these medications. Use care when operating a car or
machinery. Federal law prohibits the transfer of these drugs to any other person
other than the patient for whom they were prescribed.

110
•

The terms of this agreement are to ensure patient safety when on opioid therapy.

Patient: ________________________________Date: __________
Clinician: ______________________________Date: __________
Witness: _______________________________Date: ___________
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Appendix G: AAPM Opioid Initiation and Titration Guidelines
3.1. “Clinicians and patients should regard initial treatment with opioids as a therapeutic
trial to determine whether COT is appropriate”

3.2. “Opioid selection, initial dosing, and titration should be individualized according to
the patient’s health status, previous exposure to opioids, attainment of therapeutic
goals and predicted or observed harms”

7.1 “When repeated dose escalations occur patients on COT, clinicians should evaluate
potential causes and reassess benefits relative to harms”

7.2. “In patients who require relatively high doses of COT, clinicians should evaluate for
unique opioid-related adverse effects, changes in health status, and adherence to
the COT treatment plan on an ongoing basis and consider more frequent follow
up visits”

7.3. “Clinicians should consider opioid rotation when patients on COT experience
intolerable adverse effects or inadequate benefit despite dose increases.”

7.4. “Clinicians should taper or wean patients off of COT who engage in repeated
aberrant drug-related behaviors or drug abuse/diversion, experience no progress
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toward meeting therapeutic goals, or experience intolerable adverse effects.”

12.1. “In patients on around-the-clock COT with break-through pain, clinicians may
consider as needed opioids based upon an initial ongoing analysis of therapeutic
benefit versus risk.
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Appendix H: CDC Opioid Initiation and Titration Guidelines
#4. “When starting opioids therapy for chronic pain, clinicians should prescribe
immediate-release opioids instead of extended-release/long acting”

# 5. “When opioids are started, clinicians should prescribe the lowest effective dosage.
Clinicians should use caution when prescribing opioids at any dose, should
carefully reassess evidence of individual benefits and risk when considering
increasing dosage to >50 milligram equivalents (MME)/day or carefully justify a
decision to titrate dosage to>90 MME/day.

#7 “Clinicians should evaluate benefits and harms with patient within 1 to 4 week of
starting opioid therapy for chronic pain or of dose escalation. Clinicians should
evaluate benefits and harms of continued therapy with patients every 3 months or
more frequently. If benefits do not outweigh harms of continued opioid therapy,
clinicians should optimize other therapies and work with patients to taper opioid
to lower dosages or to taper and discontinue opioids
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Appendix I: Continuing Education Activity Evaluation Form
An Evidenced-Based Pain Management Module to Improve the Knowledge of Clinicians
Activity Title: Comprehensive Pain Management Education
Date:
As an expert in the field of pain management, Please review the educational material and
answer the following questions to the best of your ability. The comment section is to
only be used should an answer to the question fall below# 3.
Disagree

Agree

Content
1.
The content is clear and concise ....................................................... 1

2

3

4

2.

The content is capable of expanding the knowledge of clinicians....

2

3

4

3.

The content is consistent with the current practice standards and treatment
guidelines .......................................................................................... 1

2

3

4

The content is appropriate for clinicians in general and specialist
practice………………………………………………………………1

2

3

4

As an expert in pain management, I would recommend this education
to my colleagues…………………………………………………… 1

2

3

4

The content demonstrates the impotence of utilizing long-acting analgesic
in the chronic pain setting……………………………………….... 1

2

3

4

The content clearly outlines the medical and legal implications to practice
and community when opioids are used………………………… 1 2

3

4

5

2
2

3
3

4
4
4

4.

5.

6.

7.

1

Instructional Methods
1. The instructional material was well organized................................. 1
2. The instructional methods illustrated the concepts well................... 1
3. The teaching strategies were appropriate for the activity.................. 1
5

Comments:

2

3
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Appendix J: Recruitment Letter
Mark A. Wells, NP-C
164 Stratford Court
New Stanton, PA 15672
To Whom It May Concern:
My name is Mark Wells and I am currently a doctoral student at Walden University. I am
in the process of completing the university requirements, which includes a final DNP
project. This project focuses on the development of an educational module that looks to
improve the knowledge of health care clinicians utilizing an evidenced-based model. The
title of the project is “An Evidenced-Based Pain Management Module to Improve the
Knowledge of Clinicians”. You have been identified as an expert in the field of pain
management and I am writing to see if you would be willing to take part in evaluating
this projects content. The process will require that you review the educational module and
return a pre-paid stamped envelop containing the “expert-rating tool”. This rating tool
will be used to provide descriptive statistics in the body of the project. No further data
collection will be needed once this rating tool is completed and returned. I would be
happy to discuss the project further should you have any questions or concerns. I can be
reached at mark.wells@waldenu.edu or via phone at 724-454-8800. I appreciate your
time and consideration in this matter. I look forward to your response.

Sincerely,

Mark A. Wells

